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Background—American Heart Association (AHA) public policy advocacy strategies are based on its Strategic Impact Goals. 
The writing group appraised the evidence behind AHA’s policies to determine how well they address the association’s 
2020 cardiovascular health (CVH) metrics and cardiovascular disease (CVD) management indicators and identified 
research needed to fill gaps in policy and support further policy development.
Methods and Results—The AHA policy research department first identified current AHA policies specific to each CVH 
metric and CVD management indicator and the evidence underlying each policy. Writing group members then reviewed 
each policy and the related metrics and indicators. The results of each review were summarized, and topic-specific 
priorities and overarching themes for future policy research were proposed. There was generally close alignment between 
current AHA policies and the 2020 CVH metrics and CVD management indicators; however, certain specific policies still 
lack a robust evidence base. For CVH metrics, the distinction between policies for adults (age ≥20 years) and children 
(<20 years) was often not considered, although policy approaches may differ importantly by age. Inclusion of all those 
<20 years of age as a single group also ignores important differences in policy needs for infants, children, adolescents, and 
young adults. For CVD management indicators, specific quantitative targets analogous to criteria for ideal, intermediate, 
and poor CVH are lacking but needed to assess progress toward the 2020 goal to reduce deaths from CVDs and stroke. 
New research in support of current policies needs to focus on the evaluation of their translation and implementation 
through expanded application of implementation science. Focused basic, clinical, and population research is required 
to expand and strengthen the evidence base for the development of new policies. Evaluation of the impact of targeted 
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improvements in population health through strengthened surveillance of CVD and stroke events, determination of the 
cost-effectiveness of policy interventions, and measurement of the extent to which vulnerable populations are reached 
must be assessed for all policies. Additional attention should be paid to the social determinants of health outcomes.
Conclusions—AHA’s public policies are generally robust and well aligned with its 2020 CVH metrics and CVD indicators. 
Areas for further policy development to fill gaps, overarching research strategies, and topic-specific priority areas are 
proposed. (Circulation. 2016;133:e615-e653. DOI: 10.1161/CIR.0000000000000410.)
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This review offers guidance to evidence-based policy rec-ommendations across the cardiovascular continuum from 
ideal cardiovascular health (CVH) to recognized cardiovascu-
lar disease (CVD), stroke events, and their aftermath for those 
working to help achieve the American Heart Association (AHA) 
2020 Strategic Impact Goals. As context for this review, we 
highlight the methods for policy development practiced by the 
AHA, particularly its policy research department.
As organizations strategically plan their policy work and 
align their advocacy agendas with their mission and impact 
goals, they must consider criteria to assess whether, if imple-
mented, the policy change will have its intended impact. For 
the AHA/American Stroke Association, scientific and experi-
ential evidence and potential health impact, along with other 
criteria such as feasibility, positioning, and engagement, are 
used to prioritize its advocacy positions. Policy development, 
systems, and environmental change are critical strategies 
for moving large segments of the population toward better 
health.1 As part of this process, the AHA rigorously assesses 
the evidence behind its strategic planning activities and its 
reporting to key stakeholders and the public health commu-
nity. This approach can serve the AHA as a guide to further 
policy development and could be a model for other nonprofit 
organizations undertaking advocacy work.
Furthermore, the review addresses needed policy research 
in terms of 3 research functions: for current policies, to evalu-
ate their translation and implementation; for new policy devel-
opment, to expand and strengthen the evidence base; and for 
impact assessment of all policies, to monitor determinants of 
population CVH and outcomes through significantly enhanced 
surveillance at the national, state, and local levels. This need is 
discussed at 2 levels: (1) the overarching questions of imple-
mentation science, cost-effectiveness research, and impact 
evaluation and (2) specific questions relevant to each metric 
and indicator to be monitored under the 2020 goals.
Aligning the AHA’s Policy Agenda With 
the 2020 Strategic Impact Goals
The AHA’s 2020 Strategic Impact Goals target a 10-year 
20% improvement in the CVH of all Americans and a 20% 
reduction in deaths from CVDs and stroke.2 Seven metrics for 
CVH are specified separately for children (those <20 years 
of age) and for adults (age ≥20 years) and comprise 4 health 
behaviors (current smoking, body mass index, physical activ-
ity, and healthy diet score), and 3 health factors (total choles-
terol, blood pressure [BP], and fasting plasma glucose). The 
level of each metric can be graded for an individual as ideal, 
intermediate, or poor, and the 7 corresponding grades allow 
computation of an overall CVH score ranging from 0 to 14. 
The metrics and score can be assessed biennially in repre-
sentative samples of the US population through the National 
Health and Nutrition Examination Survey (NHANES) to 
monitor the nation’s CVH and the impact of policy changes, 
overall and for important subgroups.
Mortality reduction goals target deaths from CVDs and 
stroke and require improvements in acute care processes and 
medical and procedural secondary prevention therapies.1 
These comprise short- and long-term care (including rehabili-
tation) for cardiovascular and stroke events—before hospital 
admission, in the hospital, and after discharge—and interven-
tions to control the same health behaviors and factors noted 
above. Key data for monitoring the leading indicators of the 
mortality reduction goal, especially incidence, survival, and 
recurrence rates of cardiovascular and stroke events, remain to 
be developed for the US health system.
Evidence-Based Assessment: A Critical 
Part of the AHA Policy Agenda
The AHA began concerted efforts to influence cardiovascu-
lar and stroke-related public policy in the 1980s. In 2011, the 
AHA published a report summarizing its public policy agenda 
from the 1980s until that time and projected its future advo-
cacy plans.2 The AHA now has public policy initiatives at the 
federal level, in all 50 states, and in local communities. The 
policy-making process itself is complex, and there is typi-
cally a significant lag time before adoption and implementa-
tion are achieved.3 Legislative and regulatory campaigns are 
implemented by the AHA’s government relations, media 
advocacy, and grassroots network resources, all supported by 
policy research. For the AHA, assessing the evidence base is 
a significant part of the policy development process, trans-
lating science into policy solutions that have a measurable 
health impact. The AHA’s policy research department serves 
as a key link between scientists, clinicians, and policy makers, 
groups that seldom speak the same language, work on differ-
ent timelines, have different goals, and are accountable to dif-
ferent constituencies, to develop a strategic policy agenda that 
can improve CVH and decrease CVD and stroke mortality.3 
Established policies are evaluated at least on an annual basis 
for evidence of efficacy in terms of health outcomes and for 
their current importance to the overall mission of the AHA 
and are reaffirmed or revised as appropriate.
The AHA uses a comprehensive approach to determine 
its strategic policy priorities. Several issues are considered 
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and include the potential congruence of the policy with the 
AHA’s strategic priorities, impact on CVH/mortality, effect 
on social determinants of health and health disparities, fea-
sibility, likelihood of success, opportunities for engagement 
and positioning, timetable, necessary resources, and organiza-
tional engagement. Potential unintended consequences, risks, 
and impact on other policy priorities within the AHA agenda 
are also considered. This report focuses on the 2 foremost con-
siderations: alignment of a candidate policy with the overall 
AHA strategic priorities and the strength of the scientific evi-
dence to support a particular policy. (The other considerations 
will be described in detail in a future publication.)
Increasingly, the AHA is assessing the cost-effectiveness 
of interventions and incorporating economic analyses into 
its work. The AHA addressed the importance of this aspect 
of policy analysis in a previously published AHA policy 
statement,4 but more research is needed that incorporates eco-
nomic analyses into policy development, evaluation of imple-
mentation, and assessment of long-term value of the policy 
investment. The AHA has identified economic analysis as a 
Table 1. AHA Evidence Grading
Levels of Evidence
  Class I: There is evidence for and/or general agreement that the 
intervention is beneficial, useful, and effective. The intervention should 
be performed.
  Class II: There is conflicting evidence and/or a divergence of opinion 
about the usefulness/efficacy of the intervention.
  Class IIa: The weight of evidence/opinion is in favor of usefulness/
efficacy. It is reasonable to perform the intervention.
  Class IIb: Usefulness/efficacy is less well established by evidence/
opinion. The intervention may be considered.
  Class III: There is evidence and/or general agreement that the 
intervention is not useful/effective and in some cases may be harmful.
The weight of evidence in support of the recommendation
  Level of Evidence A: Data are derived from multiple randomized clinical 
trials or, given the nature of population interventions, from well-designed 
quasi-experimental studies combined with supportive evidence from 
several other types of studies.
  Level of Evidence B: Data are derived from a single randomized trial  
or nonrandomized studies.
  Level of Evidence C: Only consensus opinion of experts, case studies,  
or standard of care.
AHA indicates American Heart Association.
Table 2. The Guide to Community Preventive Services 
(Community Guide): Evidence Grading
Recommended: The systematic review of available studies provides strong 
or sufficient evidence that the intervention is effective. The categories 
of “strong” and “sufficient” evidence reflect the task force’s degree 
of confidence that an intervention has beneficial effects. They do not 
directly relate to the expected magnitude of benefits. The categorization 
is based on several factors such as study design, number of studies, and 
consistency of the effect across studies.
Recommended Against: The systematic review of available studies 
provides strong or sufficient evidence that the intervention is harmful or not 
effective.
Insufficient Evidence: The available studies do not provide sufficient 
evidence to determine whether the intervention is or is not effective. This 
does not mean that the intervention does not work. It means that additional 
research is needed to determine whether the intervention is effective.
Table 3. USPSTF Grade Definition Suggestions for Practice
A:  The USPSTF recommends the service. There is high certainty that the 
net benefit is substantial. Offer or provide this service.
B:  The USPSTF recommends the service. There is high certainty that 
the net benefit is moderate or there is moderate certainty that the net 
benefit is moderate to substantial. Offer or provide this service.
C:  The USPSTF recommends selectively offering or providing this service 
to individual patients on the basis of professional judgment and patient 
preferences. There is at least moderate certainty that the net benefit is 
small. Offer or provide this service for selected patients, depending on 
individual circumstances.
D:  The USPSTF recommends against the service. There is moderate or high 
certainty that the service has no net benefit or that the harms outweigh 
the benefits. Discourage the use of this service.
I Statement: The USPSTF concludes that the current evidence is 
insufficient to assess the balance of benefits and harms of the service. 
Evidence is lacking, of poor quality, or conflicting, and the balance 
of benefits and harms cannot be determined. Read the clinical 
considerations section of the USPSTF Recommendation Statement. If the 
service is offered, patients should understand the uncertainty about the 
balance of benefits and harms
USPSTF indicates US Preventive Services Task Force. 
Table 4. QuIC Assessment Evidence Grading
Category Description
Best In general, these components have been shown 
by rigorous peer-reviewed evidence, which was 
derived from practice or theory and research, to 
improve health across many types of settings. 
These components typically broaden the reach of 
an intervention and show a larger magnitude of 
effect. There is also likely evidence of improved 
equity and/or efficiency.
Promising Quality In general, these components have been shown 
by rigorous peer-reviewed evidence, which was 
derived from practice or theory and research, to 
improve health across a few types of settings. 
However, these components typically narrow 
the reach of an intervention and show a smaller 
magnitude of effect. There is also likely no evidence 
on equity and/or efficiency.
Promising Impact In general, the evidence shows that these 
components positively affect health across at least 
a few settings, and there might also be evidence 
of improved equity and/or efficiency. However, the 
evidence base is lacking rigorous study types, peer 
review, and a sufficient amount of evidence from 
practice or theory and research.
Emerging In general, there is very little or no evidence on 
the health, equity, and efficiency impacts of these 
components. The evidence base is also lacking 
rigorous study types, peer review, and a sufficient 
amount of evidence from practice or theory and 
research.
QuIC indicates Quality and Impact of Component.
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priority for ongoing research and will continue to integrate 
this area into its work.
The present policy review concerns primarily the evi-
dence base of the entire policy agenda conducted by the 
AHA’s policy research department. This assessment was 
based on relevant scientific guidelines and statements and 
evidence-based reviews, including, when applicable, findings 
of the Community Preventive Services Task Force and the US 
Preventive Services Task Force and results from a new method, 
the Quality and Impact of Component (QuIC) Evidence 
Assessment.4 Tables 1 through 4 show the evidence reviews 
relied on: in Table 5 for CVH metrics and in Table 6 for CVD 
and stroke mortality. For Table 5, the principal sources are the 
extensive 2012 review by Mozaffarian and colleagues5 and 
several reported by the Community Preventive Services Task 
Force.14,15 Likewise, for Table 6, 2 primary sources were relied 
on: scientific statements from the AHA/American College 
of Cardiology (ACC) and the US Preventive Services Task 
Force. The QuIC assessment is referenced in 2 areas of sugar-
sweetened beverages (SSBs) and BP. The policy priorities 
are listed in order of their level of evidence. When there was 
discrepancy between the systematic reviews for a particular 
policy priority, the most recent review incorporating the latest 
scientific evidence was given foremost consideration.
The AHA develops its guidelines through a rigorous pro-
cess, often in conjunction with the ACC, but also may develop 
them alone or collaboratively with other organizations as 
appropriate. The AHA’s guidelines reflect rigorous system-
atic review and evidence synthesis with quality grading of 
the evidence, as well as the collective judgment of leading 
experts in CVD and stroke. They undergo peer review and are 
approved by the AHA’s Science Advisory and Coordinating 
Committee.14 The Centers for Disease Control and Prevention 
(CDC)–supported Community Preventive Services Task Force 
is an independent, volunteer panel of national experts in pre-
ventive medicine and public health that provides the systematic 
reviews and recommendations summarized in the Community 
Guide. The US Preventive Services Task Force is convened by 
the Agency for Healthcare Research and Quality and is simi-
larly an independent, volunteer panel of national experts in the 
areas of clinical prevention and evidence-based medicine.
The QuIC method, developed recently by the CDC and 
collaborators, evaluates the best available evidence for a pub-
lic health policy component, including research in the peer-
reviewed literature, gray literature, and experiential evidence. 
The method categorizes the evidence along a continuum of 
strength, including emerging, promising impact, promising qual-
ity, and best (Table 4 provides definitions). The CDC’s Division 
for Heart Disease and Stroke Prevention used this method on 
components of community health worker policy7,15,16 and plans 
to use the method on other cross-cutting strategies, including 
worksite health promotion and patient-centered medical homes. 
To gain initial experience with this method and with guidance 
from CDC staff, the AHA policy research department applied 
the QuIC assessment to drinking water policy, and this analy-
sis is discussed below under Sugar-Sweetened Beverages.
Contributions to the present review from other sources 
outside of these systematic reviews are noted in the text. In 
the future, additional authoritative science reviews will be 
integrated into the AHA process, with clear guidance for rec-
onciling potential differences among their respective findings.
Purpose of This Report
In this context of AHA’s approach to policy development and 
review, the present writing group addressed the alignment 
of current AHA policies with elements of the 2020 Strategic 
Impact Goals. The intent was to ensure that policy guidance is 
in place to support advocacy and action addressing each com-
ponent of the goal, thereby maximizing the potential for its 
attainment. This assessment would also serve to identify gaps 
in policy and areas of policy development, implementation, 
and evaluation where additional research and experiential evi-
dence are needed.
Results: Alignment Between 
the Policies and Goals
Tables 5 and 6 present the main findings of this review. They 
are organized in accordance with the array of CVH metrics 
(Table 5) and CVD intervention areas (Table 6) as presented 
by Lloyd-Jones et al2 and expanded by the writing group. For 
each entry in Table 5, the criteria for ideal, intermediate, or poor 
status are indicated, separately for children and adults. It should 
be noted that although the CVH metrics are defined separately 
for children (<20 years of age) and adults (≥20 years of age), 
the policies are not always distinguished in this way; therefore, 
the alignment between age-specific metrics and corresponding 
policies is not always clear. Furthermore, in some instances, the 
designation “not prioritized” is noted, meaning that the AHA 
has elected not to develop policy specific to these targets at the 
present time. Such seeming gaps in the policy portfolio might 
be expected as a result of limitations of time and resources. In 
addition, in some cases, a metric is addressed indirectly. For 
example, body mass index (BMI) has not been prioritized 
explicitly but is addressed through policies on physical activ-
ity and diet. For each entry in Tables 5 and 6, the interventions 
supported under current AHA policies are listed in descending 
order of strength of supporting evidence. The evidence reviews 
considered by policy staff are also noted.
Cardiovascular Health
Current Smoking and Tobacco Product Use
Cigarette smoking continues to be a leading cause of prevent-
able disease and death in the United States, claiming ≈467 000 
lives prematurely every year.17 Roughly 1 in every 5 premature 
deaths in the country each year can be attributed to smoking.18 
In all analyses, mortality is higher and the quality of life is 
lower in smokers than nonsmokers at all ages.19 Although the 
health consequences of smoking are often popularly associ-
ated with lung disease and cancer, CVD is actually by far the 
leading cause of death in smokers.20 The number of cardiovas-
cular deaths worldwide resulting from smoking (1.69 million 
deaths) far exceeds either smoking-related lung cancer deaths 
(0.97 million deaths) or pulmonary disease deaths (0.85 mil-
lion deaths) alone.20 Although cardiovascular risks of smoke-
less tobacco products are lower, the use of these products is 
not without harm. Even those with low overall toxicity can 
cause important cardiovascular injury.21
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Table 5. Evidence Base Summary for the AHA Policy Portfolio Aligned With the Metrics for the AHA’s 2020 Impact Goal: 
Cardiovascular Health
Health Behaviors and Factors Policy Interventions Cited Evidence Reviews
Current smoking
 Children (12–19 y)
   Ideal: Never tried or never smoked a 
whole cigarette
  Poor: Current smoker
 Adult
  Ideal: Never smoked or quit >1 y ago
  Intermediate: quit <12 mo ago
  Poor: current smoker
Support comprehensive clean indoor air laws 
(state/community level and federal property)
AHA (Mozaffarian et al5) (see Table 1 for evidence grading): 
Class I, LOE A
Community Guide (see Table 2 for evidence grading): 
Recommended 
Increase tobacco excise taxes (federal/state/
municipal)
AHA (Mozaffarian et al5): Class I, LOE A
Community Guide: Recommended
Increase funding for tobacco cessation and 
prevention programs (state)
AHA (Mozaffarian et al5): Class I, LOE A
Community Guide: Recommended
Ensure comprehensive tobacco cessation benefits 
in private and public health insurance plans with no 
copay (federal/state)
AHA (Mozaffarian et al5): Class IIa, LOE C
USPSTF (see Table 3): A
Community Guide: recommended
Establish purchase restrictions for youth (increase 
purchasing to 21 y of age) (federal/state)
Community Guide: insufficient evidence
FDA regulation of tobacco (federal) Not available*
Monitor and regulate new tobacco products coming 
into the marketplace (federal/state)
Not available
Eliminate the sale of tobacco products in 
pharmacies and other health-related institutions 
(state/local)
Not available
BMI/healthy weight
 Children (2–19 y)
   Ideal: BMI between the 15th and 85th 
percentiles
  I ntermediate: BMI between the 85th 
and 95th percentiles
  Poor: BMI >95th percentile
 Adults
  Ideal: BMI between 18.5 and 25 kg/m2
  Intermediate: BMI 25–29.9 kg/m2
  Poor: ≥30 kg/m2
Not prioritized†
Physical activity
 Children (12–19 y)
   Ideal: ≥60 min of moderate to vigorous 
physical activity a day
   Intermediate: 1–59 min of moderate to 
vigorous physical activity a day
  Poor: no physical activity
 Adults
   Ideal: at least 150 min of moderate or 
75 min of vigorous physical activity 
each week
   Intermediate: 1–149 min/wk  
moderate or 1–74 min/wk vigorous 
activity
  Poor: no physical activity 
Improve the accountability and increase the amount 
and quality of physical education offered in schools 
(federal/state/local)‡
AHA (Mozaffarian et al5): Class IIa, LOE C
Community Guide: Recommended
PAG Mid-Course Report: Sufficient6
Implement active play and screen time standards  
in early care and education settings through 
licensing standards,‡ accreditation, quality  
rating systems, and professional credentialing 
(federal/state/local)
AHA (Mozaffarian et al5): Class I, LOE A
PAG Mid-Course Report: Suggestive
Increase the implementation of physical activity 
policies, screening, and active design in the 
worksite environment
AHA (Mozaffarian et al5): Class IIa, LOE A
Require that all road construction and reconstruction 
create “complete streets” that are safe and convenient 
for all users and modes of transportation‡  
(state/local)
AHA (Mozaffarian et al5): Class IIa, LOE B
Community Guide: Recommended
PAG Mid-Course Report: Suggestive
Increase appropriations for walking/biking and 
other active transportation opportunities in 
communities (federal/state/local)
AHA (Mozaffarian et al5): Class IIa, LOE B
Community Guide: Recommended
PAG Mid-Course Report: Suggestive
Increase funding for Safe Routes to School for 
both infrastructure- and non–infrastructure-based 
projects‡ (federal/state/local)
AHA (Mozaffarian et al5): Class IIb, LOE B
PAG Mid-Course Report: Suggestive
(Continued )
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Physical activity (continued) Target funding for improving physical  
activity environments and policy and program 
environments in communities with high need 
(federal/state)
Community Guide: Recommended
PAG Mid-Course Report: Suggestive
Implement reimbursement for and delivery 
of health/fitness counseling in an exercise 
prescription (federal/state)
AHA (Mozaffarian et al5): Class IIb, LOE C
USPSTF: B (for adults who are overweight or obese and 
have additional CVD risk factors)
PAG Mid-Course Report for Children: Insufficient
Support appropriations for state-level reporting and 
implementation of shared-use programs, as well 
as incentives to schools to promote shared use‡ 
(state/local)
AHA (Mozaffarian et al5): Class IIa, LOE A
PAG Mid-Course Report: Insufficient
Require out-of-school time programs to meet 
national standards for healthy eating and physical 
activity‡
PAG Mid-Course Report: Insufficient
Healthy diet score
 Children (5–19 y) and adults
   Ideal for cardiovascular health: in the 
context of a DASH-type dietary pattern, 
adults and children should achieve 
at least 4 of the 5 following key 
components of a healthy diet:
    Fruits and vegetables: >4.5 cups/d
    Fish: More than two 3.5-oz servings 
a week (preferably oily fish)
    Fiber-rich whole grains (>1.1 g  
fiber per 10 g carbohydrates): three 
1-oz-equivalent servings per day
   Sodium: <1500 mg/d
   SSBs: <450 kcal (36 oz)/wk
  Ideal: diet score 4–5
  Intermediate: diet score 2–3
  Poor: diet score 0–1
Overall diet:
  Promote and protect the implementation of 
robust nutrition standards for school meals  
and competitive foods‡ (federal/state/local)
AHA (Mozaffarian et al5): Class I, LOE A
  Promote robust nutrition standards in  
early care and education through licensing 
standards,‡ accreditation, quality rating 
systems, and professional credentialing. 
(federal/state/local)
AHA (Mozaffarian et al5): Class I, LOE A
  Promote evidence-based nutrition  
standards, nutrition education, physical  
activity, and screen time standards  
in before- and after-school program  
(federal/state/local)
AHA (Mozaffarian et al5): Class I, LOE A
  FDA removes “generally recognized as safe” 
status for industrially produced trans fats 
(federal)
AHA (Mozaffarian et al5): Class I, LOE B
  Eliminate unhealthy food marketing and 
advertising to children in schools and 
restaurants and by strengthening Children’s 
Food and Beverage Advertising Initiative 
voluntary standards‡ (federal/state/local)
AHA (Mozaffarian et al5): Class IIa, LOE B/Class I, LOE B
  Establish strong regulation to support and 
strengthen local school wellness policies‡  
(federal/state)
AHA (Mozaffarian et al5): Class IIa, LOE A
  Healthy food procurement on government  
property‡ (federal/state)
AHA (Mozaffarian et al5): Class IIa, , LOE B
  Ensure that calorie counts and nutrition 
information is available to consumers at the  
point of purchase on menus and menu boards‡ 
(federal/state)
AHA (Mozaffarian et al5): Class IIb, LOE A
  Secure public funding to create or expand a 
healthy corner store initiative that increases the 
amount of healthy food being offered in existing 
corner stores in low- and moderate-income 
communities‡ (federal/state/local)
AHA (Mozaffarian et al5): Class IIb, LOE B
Table 5. Continued
Health Behaviors and Factors Policy Interventions Cited Evidence Reviews
(Continued )
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Healthy diet score (continued)   Secure public funding to create or expand 
healthy food financing initiatives to increase 
the number of healthy food retail outlets in 
underserved communities‡ (federal/state/local)
AHA (Mozaffarian et al5): Class IIb, LOE C
  Finalize update of the Nutrition Facts Panel 
(federal)
Not available
  Helps shape the Dietary Guidelines for 
Americans through the regulatory process 
(federal)
Not available
Increase fruits and vegetables:  
  Advocate for adequate funding and robust 
implementation of the Fresh Fruit and Vegetable 
Program (federal)
AHA (Mozaffarian et al5): Class IIa, LOE A
  Increase the use of electronic benefit transfers at 
farmers’ markets (state/local)
AHA (Mozaffarian et al5): Class IIa, LOE A
  Increase appropriations for implementation of 
school and community gardens (federal/state)
AHA (Mozaffarian et al5): Class IIa, LOE A
  Ensure adequate nutrition services funding, 
protect and preserve the integrity of the  
Women, Infants, and Children food packages‡ 
(state/local)
Not available
Fish Not prioritized
Fiber Not prioritized
Reduce sodium
  Support FDA voluntary standards for sodium 
reduction in the food supply (federal)
Not available
  Support revisions to the Nutrition Facts Panel 
that adjust the daily value for sodium
Not available
 Reduce SSB consumption:
  Support significant increases in excise taxes on 
SSBs (federal/state/local)
AHA (Mozaffarian et al5): Class IIa, LOE B
  Remove SSBs from all restaurant children’s 
meals‡ (state/local)
AHA (Mozaffarian et al5): Class IIa, LOE B
  Remove taxes levied on bottled and vended 
drinking water‡ (state/local)
AHA (Mozaffarian et al5): Class IIa, LOE B
  Ensure that water is free, clean, and accessible 
in the school and community setting‡ (federal/
state/local)
AHA (Mozaffarian et al5): Class IIb, LOE B
QuIC: 28, Promising Quality Rating (calculated by AHA 
policy research staff)
  Support SSB warning labels (state/local) Not available
Total cholesterol
 Children (6–19 y)
  Ideal: <170 mg/dL
  Intermediate: 170–199 mg/dL
  Poor: ≥200 mg/dL
 Adults
  Ideal: <200 mg/dL
   Intermediate: 200–239 mg/dL  
or treated to goal
  Poor: ≥240 mg/dL
Not prioritized
Table 5. Continued
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Smoking claims the lives of not only those who use 
tobacco but also those who are exposed to environmen-
tal tobacco smoke. It was estimated that during 2011 to 
2012, 58 million nonsmokers in the United States were 
exposed to secondhand smoke.22 Nearly 7300 lung cancer 
and 34 000 heart disease deaths occurred during 2005 to 
2009 among nonsmokers in the United States.23 Smoking 
costs the US economy >$301 billion per year, including 
$67.5 billion in workplace productivity losses, $117 billion 
in losses resulting from premature deaths, and $116 billion 
in direct medical expenditures.24 Tobacco control efforts by 
the AHA and its public health partners have contributed to 
a relative decline in US cigarette consumption by >24% 
over the past decade.25 The various policies prioritized by 
the AHA and its national partners have included increased 
funding for tobacco cessation and prevention programs, 
comprehensive smoke-free air laws, tobacco excise taxes, 
comprehensive tobacco cessation benefits within public 
and private healthcare plans, raising the purchasing age for 
tobacco to 21 years, and US Food and Drug Administration 
(FDA) regulation of tobacco. This tobacco policy work is 
guided by decades of robust scientific evidence and serves 
as an important case study for evidence-based policy mak-
ing that can transform population health. In addition to 
the partnership engagement of the AHA with the Million 
Hearts Initiative to promote smoking cessation policies, the 
AHA’s principal policy approaches regarding tobacco are 
as follows.
Advocate for Comprehensive Clean Indoor Air Laws  
and Regulation
Advocating for comprehensive clean indoor air laws at the 
state and local levels is a pillar of the AHA’s tobacco con-
trol advocacy efforts and has led to clear health benefits.26,27 
Pooled data show that smoke-free bans reduce the incidence 
of acute coronary events by 6% to 47%, a marked change in 
a short period.27 Laws and regulations should be in compli-
ance with the Fundamentals of Smoke-Free Workplace Laws 
guidelines developed with several national partners.28
Environmental tobacco smoke (ie, secondhand smoke) 
causes heart disease, cancer, lung disease, and other illnesses 
in both children and nonsmoking adults.29,30 The direct and 
indirect healthcare costs associated with diseases caused by 
secondhand smoke exposure are estimated at $10 billion each 
year.31 If recent trends in the reduction in the prevalence of this 
exposure continue, the health and economic burden of passive 
smoking in the United States could be cut annually by ≈25% 
to 30%.30 This potential reduction has important ramifications 
for lowering expenditures by Medicare, Medicaid, and private 
insurance.
Increase Tobacco Excise Taxes and Ensure That All Tobacco 
Products Are Included
The AHA advocates for significant increases in tobacco excise 
taxes. A report from the Campaign for Tobacco Free Kids cal-
culated that if all states and Washington, DC, raised their ciga-
rette tax rates by $1 per pack, they would raise $9.1 billion in 
BP
 Children (8-19 y)
  Ideal: <90th percentile
   Intermediate: 90th–95th percentile  
or SBP ≥120 or DBP ≥80 mm Hg
  Poor: >95th percentile
 Adults:
  Ideal: BP <120/<80 mm Hg
   Intermediate: SBP=120–139 mm Hg, 
DBP=80–89 mm Hg, or treated  
<140/<90 mm Hg
   Poor: treated BP >140/>90 mm Hg  
or untreated >140/>90 mm Hg
Increase access to appropriate treatments  
(eg, help inform/guide Medicare National  
Coverage Determination) (federal/state)
Community Guide: Recommended
QuIC: Best (see Table 4 for QuIC evidence grading)
CHWs provide chronic disease care services7 
Impact score=40 (maximum)
Assure continued funding and implementation of 
Million Hearts (federal/state)
Not available
Monitor issues about drugs and devices, including 
research and adequate approval times and 
integration into delivery systems of care  
(federal/state)
Not available
Improve medication adherence (federal/state) Not available
Integrate the AHA algorithm into delivery systems 
of care (federal/state/local)
Not available
Fasting plasma glucose
 Children and adults
  Ideal: <100 mg/dL
   Intermediate: 100–125 mg/dL  
or treated to goal
  Poor: ≥126 mg/dL
Not prioritized
AHA indicates American Heart Association; BMI, body mass index; BP blood pressure; CHW, community health worker; CVD, cardiovascular disease; DASH, Dietary 
Approaches to Stop Hypertension; DBP, diastolic blood pressure; FDA, US Food and Drug Administration; LOE, Level of Evidence; PAG, Physical Activity Guidelines; QuIC, 
Quality and Impact of Component; SBP, systolic blood pressure; SSB, sugar-sweetened beverage; and USPSTF, US Preventive Services Task Force.
*Not available: the evidence reviews considered for this document did not address this policy priority, but individual studies, experiential evidence, or standard of 
care supports this work.
†Not prioritized: one of the AHA metrics not prioritized in the association’s strategic planning, so there are no aligned policy priorities.
‡Voices for Healthy Kids policy priorities, a partnership between the AHA and Robert Wood Johnson Foundation to address childhood obesity.
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new annual state tax revenues, save $52.8 billion in immedi-
ate and long-term healthcare costs, prevent >2.3 million kids 
from becoming smokers, prompt >1.2 million adult smokers 
to quit, and prevent >1 million premature deaths from smok-
ing.32 A more recent report calculated that a federal excise 
tax increase of 94 cents would prevent 1.74 million children 
from becoming addicted adult smokers over the next 18 years, 
save 989 800 Americans from premature death resulting from 
smoking, and save $63.39 billion in long-term healthcare 
costs from adult and youth smoking declines.33
Increase Funding for Tobacco Cessation and  
Prevention Programs
The AHA advocates for sustainable funding for state tobacco 
prevention and cessation programs at levels that meet or 
exceed CDC recommendations. Tobacco control programs 
should be comprehensive, developed in accordance with CDC 
recommendations, staffed appropriately, and administered 
effectively. CDC’s best practices help reduce tobacco use, 
address social norms around smoking, and support robust 
school programs, enforcement of existing regulations and 
laws, statewide programs, cessation programs, countering of 
marketing efforts (including paid broadcast and print media), 
media advocacy, public relations, public education and health 
promotion activities, surveillance and evaluation, and admin-
istration and management.
Advocate for Comprehensive Coverage of Tobacco Cessation 
Services in Private and Public Health Insurance Plans
The AHA advocates for comprehensive coverage of tobacco 
cessation services in public and private health insurance pro-
grams that include medications and counseling. Full imple-
mentation of the Affordable Care Act (ACA) has the potential 
to assist current smokers to quit because the act puts more 
emphasis on prevention in health care, including tobacco ces-
sation. Comprehensive coverage of tobacco cessation offers 
Table 6. Evidence Base Summary for the AHA Policy Portfolio Aligned With the Indicators for the AHA’s 2020 Impact Goal: CVD and 
Stroke Mortality
Indicators Policy Interventions Cited Evidence Reviews
Acute event: improve systems of 
care (acute response, acute care, 
and palliative care) for CHD, stroke, 
heart failure, and other CVDs
Support robust STEMI systems of care (state/local) ACC/AHA guidelines recommend PCI as the 
preferred strategy in STEMI, including those 
patients presenting >3 h after onset of chest pain
AHA/ACC guidelines: Class I, LOE A8
Implement robust stroke systems of care, including stroke 
telemedicine (federal/state/local)
AHA guidelines: Class I, LOE A and Class I,  
LOE B9,10
Support comprehensive, coordinated emergency medical services 
systems of care: support strengthening 9-1-1 systems,  
establish quality community CPR/AED programs, establish  
quality school-based programs, protect funding for NEMSIS  
(federal/state/local)
AHA guidelines: Class I, LOE B11,12
Support out-of-hospital cardiac arrest systems (state/local) AHA consensus statement12
Inform payment and delivery system reform efforts (federal) Not available*
Ensure optimal use of health information technology (federal) Not available
Improve the quality and comprehensiveness of healthcare data 
reporting (federal)
Not available
Increase the use of clinical registries (federal/state) Not available
Integrate the AHA’s principles for palliative care within delivery of 
care (federal)
Not available
Ensure implementation of pulse oximetry for newborns (federal/state) Not available
Explore evidence-based opportunities for integration with mobile 
health technologies in delivery systems of care (federal)
Not available
Postevent rehabilitation: increase 
referral to, use of, adequate 
reimbursement for, and completion 
of CR and SR
Increase referral and use of CR by decreasing copays, increasing the 
healthcare professionals who can supervise CR, expanding coverage 
for heart failure patients, and allowing patients to move more easily 
between intensive CR and regular CR (federal)
AHA guidelines: Class I, LOE A13
Assure adequate coverage/reimbursement for comprehensive stroke 
rehabilitation (federal)
AHA guidelines: Class I, LOE A9
Broadly implement automatic and coordinated referral strategies 
(federal/state)
AHA guidelines: Class III
ACC indicates American College of Cardiology; AED, automated external defibrillator; AHA, American Heart Association; CHD, coronary heart disease; 
CPR, cardiopulmonary resuscitation; CR, cardiac rehabilitation; CVD, cardiovascular disease; LOE, level of evidence; NEMSIS, National EMS Information System; 
PCI, percutaneous coronary intervention; SR, stroke rehabilitation; and STEMI, ST-segment–elevation myocardial infarction.
*Not available: the evidence reviews considered for this article did not address this policy priority, but individual studies, experiential evidence, or standard of care 
supports this work.
e624  Circulation  May 3, 2016
new opportunity to encourage tobacco cessation, to minimize 
tobacco use, or to switch to modalities of uncertain benefit 
such as electronic cigarettes (e-cigarettes). In general, facili-
tating tobacco cessation remains a highly cost-effective strat-
egy, although it is very difficult for most people to quit this 
deadly, addictive habit.34 Available forms of nicotine replace-
ment therapy (gum, transdermal patch, drugs for smoking 
cessation, nasal spray, inhaler, and lozenges) increase quit 
rates by 50% to 100% compared with not using any of these 
products; however, <1 in 5 smokers making an attempt to quit 
takes advantage of these therapies.35 The most successful pro-
grams have a 1-year quit rate of ≈35% (compared with 5% 
for unsupported attempts) and cost about $1500 per quitter 
at a cost of $202 per life-year saved with a return on invest-
ment of $5.45 for every $1 of program cost.36 Therefore, the 
AHA supports not only comprehensive coverage of tobacco 
cessation but also wide dissemination of these programs and 
recruitment of individuals who plan to quit but could not or 
have not taken advantage of these interventions.
Promote Tobacco 21
Tobacco 21 is an emerging policy strategy to reduce youth 
tobacco use because most adults start smoking tobacco before 
21 years of age.37 Modeling research has shown that raising the 
purchasing age may reduce the smoking rate by 12%, reduce 
smoking-related mortality by 10%, and lead to 249 000 fewer 
premature deaths and 4.2 million fewer years of life lost.37 
The AHA has recently added this priority to its tobacco policy 
agenda and will continue to evaluate the emerging research 
addressing its effectiveness.
Provide FDA Regulation of Tobacco
AHA worked with Congress to pass the 2009 Family Smoking 
and Tobacco Control Act.38 This legislation, for the first time, 
gave the FDA the oversight authority to regulate tobacco 
products and to restrict tobacco company efforts to addict 
more children and adults. The AHA continues to work with 
the FDA and the Center for Tobacco Products to provide 
evidence and advice with potential to facilitate the develop-
ment and implementation of FDA regulatory and other policy 
recommendations.
Regulate e-Cigarettes and Other New Tobacco Products
In recent years, the advent of e-cigarettes has significantly 
changed the tobacco landscape. Current population surveys 
show that 3% to 7% of the adult population has used e-ciga-
rettes.39 Among students in grades 6 through 12, current e-cig-
arette use has increased from 1.1% in 2011 to 2.1% in 2012, 
and ever e-cigarette use increased from 3.3% to 6.8% in the 
same years.40,41 By 2012, 1.78 million high school and middle 
school students nationwide had tried e-cigarettes.41 E-cigarette 
sales have been projected to increase from $2 billion in 2012 
to top $10 billion in 2017.42
Proponents of e-cigarettes maintain that these products 
emulate smoking behavior without exposing the user to the 
combustible products found in conventional cigarette smoke 
that are deleterious to health.43 They argue that the use of 
e-cigarettes could potentially reduce exposure to these harm-
ful combustion products.44 Some e-cigarette enthusiasts suggest 
that e-cigarettes are less addictive than conventional cigarettes 
and that their use could be a viable intermediate step in cessa-
tion. However, the long-term health effects of e-cigarette use 
and their efficacy as a primary cessation aid remain unclear.42,45 
Moreover, the increased prevalence of e-cigarette use, regard-
less of the reason, has the potential of renormalizing smoking.42 
Reducing the visibility of cigarettes has been one of the most 
successful strategies for tobacco control. Their increased visibil-
ity in public places and advertisements could significantly erode 
previous gains in removing tobacco products from the public 
eye.42 Additionally, the use of e-cigarettes might serve as a gate-
way to the use of other drugs and harmful substances, especially 
among youth and other susceptible groups.46 Although contin-
ued research is required to assess the health and socioeconomic 
impacts of e-cigarettes, the AHA recognizes the recent increase 
in e-cigarette use and has published a policy statement42 that 
both outlined how e-cigarettes should be addressed in existing 
tobacco control and prevention efforts and reinforced the need 
for further research on the cardiovascular effects of e-cigarettes, 
their efficacy as a cessation aid, and their role in youth/adoles-
cent addiction to nicotine. The AHA considers e-cigarettes that 
contain nicotine to be a tobacco product and therefore supports 
their regulation under existing laws related to the use and mar-
keting of tobacco products.
Eliminate the Sale of Tobacco Products in Pharmacies and 
Other Health-Related Institutions
The AHA supports policies that prohibit the sale of tobacco 
products in all healthcare settings, including pharmacies, and 
considers it incongruous for tobacco products to be sold in any 
setting that purports to promote health. The prevailing view in 
the public health community is that tobacco products, includ-
ing e-cigarettes, should not be sold in pharmacies. For exam-
ple, CVS Pharmacy made a significant public health statement 
by removing tobacco products from its stores and by support-
ing both tobacco cessation and prevention programs with 
corporate grants and a school-based program in communities 
across the country. The CVS Health Research Institute found 
that 8 months after CVS stores stopped selling tobacco prod-
ucts, there was an additional 1% decrease in cigarette pack 
sales in states with a CVS Pharmacy market share of ≥15% 
compared with states with no CVS Pharmacy stores.47 Over 
that same 8-month period, the average smoker in these states 
purchased 5 fewer cigarette packs, and in total, ≈95 million 
fewer packs were sold.47
BMI (Not Prioritized, Although Implied Within Physical 
Activity and Dietary Policies)
Obesity is an important underlying cause of CVD and other 
adverse health outcomes.48 The prevalence of overweight 
and obesity has been increasing in children, adolescents, and 
adults in the United States and elsewhere.49 Once it develops, 
obesity tends to persist. For example, an obese adolescent is 
highly likely to become an obese adult. This in turn places 
obese individuals at risk for CVD,50 including ischemic heart 
disease51 and stroke,52 as well as type 2 diabetes mellitus53 and 
obstructive sleep apnea.54
BMI is a useful measure of obesity and adiposity in the 
clinical setting.55 It is easy to compute from measures of 
height and weight and is commonly used in national sur-
veys such as NHANES.56 The AHA includes BMI as one of 
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4 health behaviors to track for the 2020 Strategic Impact 
Goals. Although not solely as a result of health behavior, 
having metabolic complements as well, BMI reflects the bal-
ance of energy intake and output resulting from dietary and 
physical activity behaviors, such that positive energy balance 
(excess of intake over output) increases adiposity.
Although not explicitly prioritized by the AHA in its pol-
icy agenda, the association has adopted the American Medical 
Association’s Expert Committee recommendations on the 
assessment, prevention, and treatment of child and adolescent 
obesity.57 These include regular BMI assessment during clinical 
visits, appropriate behavioral counseling to improve diet and 
physical activity behaviors, provider training and continuing 
education on best practice in delivering behavioral interven-
tions, surveillance of BMI in schools and at the state level, and 
support for measurement and recording of BMI as a Healthcare 
Effectiveness Data and Information Set measure. Clinicians 
identify overweight and obese children according to their 
BMI.58 Advocacy for this clinical approach, including evalu-
ation of the effectiveness of BMI assessment as a Healthcare 
Effectiveness Data and Information Set measure, has dramati-
cally improved the measurement of BMI in clinical settings.
The US Preventive Services Task Force found that behav-
ioral intervention for treatment of obesity can be safe and 
effective in lowering BMI.59 An emerging policy area for the 
AHA is to determine best practices and policy solutions for 
integrating lifestyle behavioral counseling and treatment into 
delivery systems of care, taking into account the costs and 
value of this investment and determining optimal reimburse-
ment structures. Some further policy approaches may include 
ensuring BMI assessment, training of healthcare providers in 
behavioral intervention, and linking providers with commu-
nity resources to support patient referral for treatment.
Surveillance of BMI in schools has been controversial, 
chiefly because of concerns about labeling children as over-
weight or obese, but can be useful as part of an overall approach 
to lower the prevalence of obesity in school children.60 When 
properly introduced in an objective manner, BMI measure-
ment can provide useful information for parents and primary 
care physicians or other providers to decide whether diet and 
other lifestyle intervention is warranted and, if so, what the 
most effective approach might be. Respecting privacy, applying 
deidentified data at a state level can be useful in evaluating the 
success of statewide obesity intervention programs.
There is a strong need to establish environmental policy 
that offers people the opportunity to make healthful choices. 
Availability of recommended foods such as fruits, vegetables, 
whole grains, fish, poultry, and lean meats is necessary, if not 
sufficient, to increase the likelihood that such foods will be con-
sumed. Likewise, providing safe, well-lighted streets, sidewalks, 
parks, and recreational facilities improves the chances that peo-
ple will be more active. Prevention of overweight and obesity 
is a critical aspect of improving the CVH of the United States.
Physical Activity
The current prevalence and global reach of physical inactivity 
have been described as a pandemic with far-reaching health, 
economic, and social consequences.61,62 The cardioprotective 
effects of regular moderate to vigorous physical activity are 
well established.63 There is growing evidence of the negative 
health consequences of sedentary time that are independent 
of moderate to vigorous physical activity such as weight gain, 
type 2 diabetes mellitus, CVD, cancer, and total mortality.64 
Unfortunately, in a comparison across 10 developed countries, 
US children had the lowest measure of physical activity, half 
the amount of the highest country.65 As a nation and across 
the globe, we are increasingly becoming more sedentary.66 
Fewer than half of US adults (48%) meet the Physical Activity 
Guidelines for Americans,67 and this is largely from self-
reported data. Actual, objectively measured levels of physical 
activity in the adult population are even lower.68
A wide range of evidence-based physical activity inter-
ventions target individuals, groups, schools, early child care, 
workplaces, other organizations, and community built envi-
ronments.5,69,70,71,72 Policies can facilitate widespread imple-
mentation of effective physical activity interventions by 
setting standards, requiring programs, providing incentives 
for individual behavior change, and requiring or funding built 
environment changes.
The AHA has adopted policy goals related to school/early 
child care, workplace, and community physical activity inter-
ventions. Further research is needed to identify effective and 
cost-effective interventions for reducing sedentary behavior. 
Estimates suggest that $5.6 billion in heart disease costs could 
be saved if 10% of Americans began a regular walking pro-
gram.73 Most of the physical activity policies shown in Table 6 
are supported as evidence-based strategies. Policy targets 
include the following.
Improve Physical Education in Schools and Accountability 
for Program Quality
Most school-based policies promote programs that have been 
evaluated in controlled trials. Enhanced physical education 
programs that emphasize more class time spent in moder-
ate and/or vigorous physical activity increase the amount of 
time students spend in moderate to vigorous physical activ-
ity by 10%.74 Policy interventions involving increased staff 
training increased moderate to vigorous physical activity by 
18% after a 2-year follow-up.75 A physical education pro-
gram that includes the provision of equipment, staff train-
ing, a teaching assistant, and an updated curriculum can be 
successfully implemented in schools to ensure that partici-
pants spend at least 50% of the class engaged in moderate 
to vigorous physical activity.76 Children average 25 more 
minutes of physical education per week when a gymnasium 
is available.77
Mandated physical education policy in schools may have 
the greatest physical activity–related energy expenditure 
among all school- and community-based policies.78 Students 
in policy-compliant districts are nearly 30% more likely to 
be physically fit than those in noncompliant districts.79 Long-
term exercise programs for children have been shown to 
reduce BMI and diabetes mellitus risk factors and to improve 
cardiovascular risk factors such as cholesterol and BP.80,81
Implement Active Play and Screen Time Standards in Early 
Care and Education Settings
Emerging evidence supports the effectiveness of early care 
and education standards for physical activity and screen time 
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through licensing laws and regulation, accreditation, qual-
ity rating improvement programs, and professional develop-
ment opportunities for staff.82 A recent study by Gortmaker 
et al83 showed that early care and education interventions 
could reach a population of 1.18 million, preventing 38 400 
childhood obesity cases if implemented nationally, at a cost 
of $613 per BMI unit change. The Robert Wood Johnson 
Foundation maintains that children’s social and economic 
conditions have direct effects on health and that children 
who participate in high-quality early childhood develop-
ment programs experience a range of health benefits that 
have short- and long-term impact.84 Appropriations will 
have to ensure that resources are getting to centers in vul-
nerable communities to implement the nutrition and physi-
cal activity standards.
Increase Physical Activity Screening, Policies, and Active 
Design in the Workplace Environment
The workplace is an important setting for reaching the mil-
lions of employed adults with health-related interventions 
where they are spending a majority of their day. Overall, as 
occupations have become more sedentary, calorie expendi-
ture at work has decreased over the past 5 decades by >100 
cal/d.85 Fitness in the workplace correlates with more than just 
health. It has also been associated with a 5% to 10% wage 
increase,86 increased overall family earnings,87 lower debt, and 
lower long-term unemployment.88 Business-related outcomes 
related to employee fitness include reduced absenteeism, 
productivity gains, lower healthcare costs, lower turnover, 
decreased short-term disability, and improved employee job 
satisfaction and work performance.88
 The interventions have to go beyond simple program-
ming to include workplace culture, occupational safety, 
active design policies for sedentary environments, leader-
ship role modeling, and policies to promote physical activ-
ity and physical fitness. The AHA supports comprehensive 
worksite wellness programs89,90 and will continue to respond 
to regulation around worksite wellness programs and health 
risk/biometric assessments. The AHA will strive for regu-
lation that protects employees and motivates employers to 
continue to sponsor comprehensive, evidence-based inter-
ventions. Further research is needed to understand the 
impact of incentive design, mobile health technologies, 
environmental design, workplace culture, and polices on 
promoting physical activity and physical fitness within the 
worksite environment.
Increase Adoption of Active Design and Active Transportation 
in Communities, Including Complete Streets Policies, Walking 
and Biking Trails, and Safe Routes to School
Complete Streets policies direct transportation agencies and 
engineers to develop streets that are safe for all users regard-
less of age, ability, or mode of transportation (eg, cars, pub-
lic transit users, bicyclists, and pedestrians) to move through 
the community. Policies that improve built environments 
are based on cross-sectional studies and quasi-experimental 
evaluations of “natural experiments.” Nevertheless, there is 
substantial documentation of the importance of community 
design, mixed land use, and connected streets (ie, walkable 
neighborhoods) in facilitating walking for transportation.6 
Changes in zoning laws are needed to achieve these types of 
built environments. Evidence of the importance of street-level 
design of sidewalks and street crossings is encouraging but 
limited,91 so further research is needed. Improving pedestrian 
and bicycling facilities is the goal of Complete Streets poli-
cies. Some research has shown that Complete Streets policies 
can lead to a 50% increase in the number of walkers92 and a 
35% increase in overall physical activity.72 Recent evidence 
supports the effectiveness of federal Safe Routes to School 
policies and funding for increasing physically active travel to 
and from school.93,94
Implement Reimbursement for and Delivery of Physical 
Activity/Physical Fitness Counseling With an Exercise 
Prescription and Integrated Systems of Care
International studies support healthcare provider referrals 
to intensive diet and exercise counseling in community 
settings,95 but more studies conducted in the United States 
are needed. An analysis by the CDC showed that in 2013, 
36.8% of US adults (89 million) met the criteria to be classi-
fied as eligible for intensive behavioral counseling for CVD 
prevention, including 40% of men and 33.5% of women.96 
Nationwide, ≈20% of adults were eligible and did not meet 
the criteria for aerobic physical activity, meaning that there 
are ≈47.8 million adults in the United States who currently 
should have been receiving physical activity counseling 
and could be provided an exercise prescription.96 The vast 
majority of primary care providers do not feel comfortable 
discussing behavioral changes in the context of physical 
activity. Much more research and modeling are needed to 
determine the optimal delivery systems of care and potential 
role for mobile health technologies.
Shared Use Programs
Shared use of school facilities for community recreation is a 
promising policy, but further evaluation is needed to deter-
mine the effectiveness of uptake and implementation of 
policies.97 This policy work is generally targeted to reduce 
disparities in access to recreation facilities. Pilot research 
has shown that children are significantly more likely to be 
physically active when they have access to fields and play 
areas after school98 and that children are 84% more physically 
active in communities that have shared use agreements,99 but 
more research is needed.
Support Physical Activity and Screen Time Standards  
in Out-of-School Time Programs
There is limited evidence for the effectiveness of standards in 
before- and after-school programs,100 so further evaluation of 
these strategies is needed.
Future Policy Considerations
Changing national and state transportation goals from an 
automobile orientation to a balanced multimodal system 
could shift priorities and funding to walking and bicycling.100a 
Oregon implemented such policies, providing a successful 
case example.101
Policies to reduce disparities in physical activity and to 
improve CVD outcomes should be considered. Proximity 
to parks is related to physical activity in youth and adults, 
yet low-income and mostly minority neighborhoods are 
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less likely to have parks.102,103 Thus, policies to require 
parks within walking distance of all homes could reduce 
disparities.
Healthy Diet Score
The AHA’s healthy diet score comprises 5 primary metrics: 
intake of fruits and vegetables (≥4.5 cups/d), seafood con-
sumption (2 or more 3.5-oz servings per week, preferably 
oily fish), intake of fiber-rich whole grains (3 or more 1-oz-
equivalent servings per day of ≥1.1 g fiber per 10 g carbohy-
drate), sodium intake (to ≤1500 mg/d), and limiting SSBs to 
450 kcal (≤36 oz)/wk.2 In addition, secondary goals address 
legumes, nuts, and seeds (4 servings a week); processed 
meats (none or no more than 2 servings a week); and satu-
rated fat (<7% of total energy intake,2 with a specific target of 
5%–6% of calories along with minimal intake of trans fat).104 
These specific goals are set within the context of a healthy 
dietary pattern. Currently, stratification of the healthy diet 
metrics is binary (yes/no) in nature. However, as the AHA’s 
strategic planning and outcome evaluation procedures evolve, 
the association may adopt a graded or continuous measure 
to recognize gradual improvements in diet. Strategically, the 
AHA has emphasized a subset of the diet metrics to reach its 
2020 goal: reducing SSB consumption, reducing sodium, and 
increasing fruit and vegetable intake. However, several AHA 
policy priorities using systemic interventions are intended to 
benefit the overall diet.
Overall Dietary Pattern
The dietary pattern based on the Dietary Approaches to 
Stop Hypertension (DASH) study is widely advocated.105 
This eating pattern represents intake of nutrients, foods, and 
food groups that both support optimal nutritional status and 
decrease cardiometabolic risk among different age, sex, and 
ethnic groups.106,107 Although studies have often focused on 
single nutrients, including saturated fat, dietary cholesterol, 
sodium, and polyunsaturated fatty acids, the current recom-
mendations reflect more recent findings documenting the 
benefits of a DASH-like eating pattern that is consistent with 
studies that have achieved successful adherence with benefi-
cial CVH results.108–110 These eating patterns are associated 
with improved cardiovascular outcomes and reduced morbid-
ity and mortality from chronic diseases.111
The 2015 US Dietary Guidelines Advisory Committee 
reviewed 142 articles on dietary patterns and CVD that 
met established criteria.112 Included were 55 articles sum-
marizing the findings of 52 prospective cohort studies and 
7 randomized, controlled trials, as well as the 2013 AHA/
ACC lifestyle guideline and associated National Heart, 
Lung, and Blood Institute lifestyle report, both based pri-
marily on randomized, controlled trials. In addition, the US 
Dietary Guidelines Advisory Committee took into account 
the results of 6 systematic reviews/meta-analyses published 
since 2008, including several studies not included in those 
previous guidelines. Their conclusion is congruent with 
AHA policies:
Dietary patterns characterized by higher consump-
tion of vegetables, fruits, whole grains, low-fat dairy, 
and seafood, and lower consumption of red and pro-
cessed meat, and lower intakes of refined grains, and 
sugar-sweetened foods and beverages relative to less 
healthy patterns; regular consumption of nuts and 
legumes; moderate consumption of alcohol; lower in 
saturated fat, cholesterol, and sodium and richer in 
fiber, potassium, and unsaturated fats.105
Moreover, the 2015 Dietary Guidelines for Americans 
recently issued recommendations for 3 food-based dietary 
patterns (healthy US-style pattern, healthy Mediterranean-
style pattern, and the healthy vegetarian pattern) that are con-
sistent with AHA policies.113
Overall diet policy interventions currently supported by 
the AHA include the following:
1. Promote and protect the implementation of robust nutri-
tion standards for school meals and competitive foods.
The federal meal and Smart Snack standards double the fruit 
and vegetables served to children at mealtimes, reduce sodium, 
increase whole grains, and offer healthy beverages. Many stu-
dents consume up to half of their daily calories at school.114 In 
a recent study, robust nutrition standards for school meals and 
competitive foods reached a large population of children (50 
million children attend kindergarten through grade 12 schools 
each day) and predicted that the new standards would prevent 
an estimated 1.8 million cases of obesity at a cost of $53 per 
BMI unit change.83
2. Promote robust nutrition standards in early care and 
education.
The evidence base for early care and education interven-
tions is reviewed in the physical activity section (above) 
and is an emerging area of research with early indications 
of success for establishing important foundations for 
healthy living.
3. Promote evidence-based nutrition standards and nutri-
tion education in before- and after-school programs.
The evidence regarding out-of-school time interventions 
is also reviewed in the physical activity section. Significant 
additional research is warranted to determine the efficacy and 
impact of the current nutrition standards.
4. Eliminate unhealthy food marketing and advertising to 
children in schools and restaurants.
A report from the Federal Trade Commission115 revealed that 
industry spent nearly $1.8 billion in 2009 on marketing and 
advertising foods and beverages to children. The top 3 topics 
were fast food ($714 million), carbonated beverages ($395 
million), and breakfast cereals ($186 million).115 The fast-
food industry spends nearly $2 million every day on adver-
tising to children.115 On average, children are exposed to 13 
food advertisements every day and >40 000 advertisements 
per year on television alone.116 It is difficult to measure the 
direct impact on CVH of eliminating marketing of unhealthy 
foods and beverages to children (or conversely using brands 
and characters to market only healthy foods). Systematic 
reviews have shown some positive benefit of such interven-
tions on the quality of children’s diets, but larger studies in 
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more diverse populations are needed for better assessment of 
health impact.117,118
5. Establish strong regulation to support and strengthen 
local school wellness policies.
Although in principle a promising strategy, there is little evi-
dence to date for the health impact of local school wellness 
policies. Most schools are implementing the federal law, but 
policies are weak with little transparency.119 A final school 
wellness policy rule that would increase transparency and 
accountability had not been released by the US Department of 
Agriculture as of December 2015.
6. Promote healthy food service and food procurement on 
government property.
Currently, federal, state, and local governments employ ≈22 
million people: State governments employ 5.3 million peo-
ple; local governments, 13.8 million people; and the federal 
government, 2.7 million people.120 There are 9 million veter-
ans and employees reached with the Department of Veterans 
Affairs guidelines with >37 million meals served a year and 
35 000 vending machines within that agency.121 More than 100 
million Americans eat from food service meals each day in 
which government guidelines or the AHA’s standards may be 
implemented by large employers, entertainment venues, faith-
based organizations, recreational centers, and hospital sys-
tems.121,122 In this emerging policy area, much more research is 
needed to determine the effectiveness of implementation and 
the health impact of procurement standards and food service 
guidelines.
7. Secure public funding for healthy food financing initia-
tives and healthy corner store initiatives.
This policy initiative is targeted at vulnerable communi-
ties. A 2013 report from Policy Link and The Food Trust 
found that urban communities of color and rural commu-
nities, especially Native American reservations, lacked 
access to healthy food, especially compared with higher-
income and white neighborhoods.123 Although a significant 
amount of public and private investment has been made in 
healthy food financing initiatives at the federal, state and 
local levels, most of the research to date has addressed the 
amount of economic investment brought into underserved 
neighborhoods, not the impact on consumer purchasing 
behavior or health benefits.123 However, in a recent RAND 
study,124 residents’ diets improved in some ways (fewer cal-
ories, less added sugar, fewer empty calories from saturated 
fat, added sugars, and alcohol) in an intervention commu-
nity where a supermarket had been built, but there was no 
improvement in intake of whole grains or fruits and veg-
etables. Additionally, the dietary improvements were not 
necessarily linked to the presence of the store itself but may 
have resulted from the campaign to bring the supermarket 
to the community, which had raised consumer awareness. 
Residents in the intervention community had a better feeling 
about food access in their community. Much more research 
is needed to determine whether there is a health benefit in 
bringing supermarkets, grocery stores, or healthy corner 
stores to underserved communities and to assess whether 
there is actually a marked increase in healthy food access 
and that consumers are purchasing and consuming healthier 
foods and beverages.
8. Advocate for improved food labeling and updating the 
Nutrition Facts Panel.
The Nutrition Facts Panel is one of the most prominent 
sources of nutrition information on prepackaged foods 
and is perceived by consumers as a highly credible source 
of information with wide reach across the population.125 
Systematic review has shown consistent a link between 
use of labels and healthier diets. However, such use is less 
frequent among some groups, for example, children, ado-
lescents, and obese older adults, and understanding and 
appropriate use of the nutrition information are limited 
among less educated consumers.125–127 In summary, there 
is some link between the use of the Nutrition Facts Label 
and healthier diets, but there are not yet conclusive data on 
CVH outcomes.
9. Support application of the Dietary Guidelines for 
Americans to federal feeding programs.
Higher dietary quality consistent with the Dietary Guidelines 
for Americans has been shown to decrease the risk of CVD 
and other chronic diseases.111,128,129 There is a great popu-
lation health benefit with adequate implementation of the 
Dietary Guidelines for Americans across federal feeding 
programs. For example, 30.3 million students in school are 
served by the school meal program129a; 9 million women, 
children, and infants are fed by the Supplemental Nutrition 
Assistance Program for Women, Infants, and Children129b; 
3.4 million children are fed 1.9 billion daily meals and 
snacks by the Child and Adult Care Food Program129c; and 
>43 million people are served by the Supplemental Nutrition 
Assistance Program,129d representing a sizeable portion of 
the US population.
Future policy development should consider linking provi-
sion of any amount of federal, state, and local reimbursements 
by programs/organizations to a requirement that all foods 
and beverages provided by those programs or sold by those 
organizations meet the Dietary Guidelines for Americans. 
Additionally, health-related programs receiving federal mon-
ies should have education programs to teach healthy lifestyle 
behaviors and should evaluate the effectiveness of any of their 
lifestyle interventions. Currently, <1% of children meet all 5 
criteria for a healthy diet, although it is recognized that the bar 
is set high, for example, for fruit and vegetable intake, for their 
size and caloric needs. This fact calls attention to an urgent 
need for policy implementation to improve CVH beginning 
early in life. We turn now to specific indicators of a healthy 
dietary pattern.
Fruits and Vegetables
Health benefits associated with increasing consumption of 
fruits and vegetables include lower risks of CVDs, stroke, 
and cancer among adults and children.130,131 Accordingly, 
the AHA has established several policy priorities related 
to intake of fruits and vegetables. With proper planning, 
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increased intake of fruits and vegetables can be accom-
plished without increasing overall consumption of calo-
ries or increasing costs. It is estimated that $17 billion in 
annual national medical costs could be saved if Americans 
followed dietary recommendations for fruit and vegetable 
consumption.132
1. Advocate for adequate funding and robust implementa-
tion of the Fresh Fruit and Vegetable Program.
The Fresh Fruit and Vegetable Program operates in 
selected low-income elementary schools in the 50 states, 
the District of Columbia, Guam, Puerto Rico, and the 
Virgin Islands and currently provides $158 million in 
assistance to state agencies.133 States then select schools 
to participate on the basis of criteria in the law, includ-
ing the requirement that each student receives between $50 
and $75 worth of fresh produce over the school year.133 
Depending on enrollment and the allotment spent on each 
child, the US Department of Agriculture estimated that 
the expanded assistance helped schools serve an addi-
tional 600 000 to 950 000 students in the 2011 to 2012 
school year.133 Research has shown that the Fresh Fruit and 
Vegetable Program increases fruit and vegetable consump-
tion in children134,135 and can decrease obesity in those who 
participate.136 An independent evaluation found that the Fresh 
Fruit and Vegetable Program increased students’ average fruit 
and vegetable consumption by 15% in participating schools 
but did not increase overall caloric intake, suggesting that 
children replaced less healthy foods in their diets with fruits 
and vegetables.137
2. Increase the use of electronic benefit transfers at farmers’ 
markets.
There is no specific research on the impact of electronic ben-
efit transfers use and CVH. However, on the basis of current 
evidence, price reduction policies would have favorable rela-
tive effects on non-Hispanic whites and blacks, providing a 
way to reach areas without easy access to fresh foods138–142 and 
helping to create equitable food systems.143
3. Increase appropriations for implementation of school 
and community gardens.
Systematic reviews have shown that garden-based inter-
vention programs in schools and communities have the 
potential to increase fruit and vegetable intake in children 
and to increase their willingness to taste fruits and veg-
etables. However, empirical health outcome data are not 
currently available.144,145 Funding is typically modest and 
targeted to low-income communities, addressing food inse-
curity, nutrition education, and healthy food access. The 
Farm to School program, housed in the US Department of 
Agriculture Food and Nutrition Service, was authorized in 
the 2010 Healthy Hunger Free Kids Act and to date has 
funded 221 projects totaling $15.1 million.146 There are 
other federal, state, and local government sources of grant 
funding for school and community garden programs,146a as 
well as funding from industry, foundations, nonprofit organi-
zations, and crowd sourcing.
4. Ensure adequate nutrition services funding and protect 
and preserve the integrity of the Women, Infants, and 
Children food packages.
A systematic review demonstrated improved dietary intake 
in Women, Infants, and Children participants and increased 
availability of healthier foods and beverages in authorized 
Women, Infants, and Children stores.147 Further research is 
needed on the CVH impact of this policy and on the uptake 
of breastfeeding.
To achieve better access to a plant-based eating pattern, 
future advocacy may target the food system and food produc-
tion, for example, supporting farmers who grow fruits and 
vegetables. Without adequate supply, meeting the recom-
mended intake of fruits and vegetables would not be possible, 
and the cost to consumers would be prohibitive.
Sugar-Sweetened Beverages
In a systematic review and meta-analysis of prospective 
cohort studies and randomly controlled trials, researchers 
demonstrated that SSB consumption resulted in unwanted 
weight gain in children and adults.148 Consumption of SSBs 
is currently the single largest category of caloric intake in 
children, accounting for 10% to 15% of their total daily 
calories.149–151 Data from the 2010 National Youth Physical 
Activity and Nutrition Study found that high school stu-
dents consumed ≥1 SSBs daily, including regular soda 
(25%), a serving of a sports drink (16%), and another SSB 
(17%).152 In a trend and cross-sectional analysis from the 
NHANES for the period from 1999 to 2000 through 2007 
to 2008, the prevalence of heavy SSB consumption (≥500 
kcal/d) increased among children (4% to 5%) but decreased 
among adolescents (22% to 15%) and young adults (29% 
to 20%).153 Soda was the most heavily consumed SSB in all 
age groups except children.
Although the prevalence of soda consumption decreased, 
heavy sports/energy drink consumption tripled (4% to 12%) 
among adolescents.153 Notable for targeted SSB interven-
tions, black children and adolescents had higher prevalence 
odds ratios of heavy fruit drink consumption (odds ratio, 1.71 
and 1.67, respectively) than their white counterparts.153 Low-
income children had higher odds of heavy total SSB consump-
tion (odds ratio, 1.93) and higher caloric intake from total 
SSBs and fruit drinks (by 23 and 21 kcal/d) than their high-
income counterparts.153 In addition, among adults, low versus 
high socioeconomic status was associated with higher odds 
of heavy consumption of total SSBs, soda, and fruit drinks.153 
Whereas recent evidence suggests that intake of SSBs has 
declined in certain segments of the population, this is not true 
across the entire population.154,155 Taken together and viewed 
in the context of emerging research on SSBs, the disparity in 
heavy consumption of SSB types across racial/ethnic subpop-
ulations and higher odds of heavy SSB consumption among 
low–socioeconomic status populations indicate the need for 
targeted interventions within environmental and policy initia-
tives designed to improve dietary patterns of all US children, 
adolescents, and adults.
Both environmental and policy initiatives promote healthy 
beverage consumption.156 Individuals are influenced by daily-
life exposures in their environment157 that influence patterns 
e630  Circulation  May 3, 2016
of eating behavior, including the selection and consumption 
of food.158–160 The AHA has advocated for several policy initia-
tives in this area.
1. Support significant increases in excise taxes on SSBs.
A systematic review of some 160 studies found that food 
consumption away from home was most responsive to price 
changes.161 A price increase in soda and away-from-home 
foods was found to be associated with lower caloric intake, 
healthier weight, and decrease diabetes mellitus risk.162 
In another study, investigators suggested that a 10% price 
increase can decrease consumption of these foods and bever-
ages by 8% to 10%.163 Food choices by vulnerable popula-
tions, those that have the greatest negative health disparities 
(ie, children and adolescents, low-income and less well-edu-
cated individuals), are particularly price sensitive.164–166 One 
modeling study showed that an excise tax would reduce SSB 
consumption by 20% and mean BMI by 0.16 units among 
youth and 0.08 units among adults in the second year for a 
cost of $3.16 per BMI unit reduced.167 It also would avert 
a loss of 100 000 disability-adjusted life-years, produce a 
gain of 871 000 quality-adjusted life-years, result in $23.6 
billion in healthcare cost savings, and generate $12.5 billion 
in annual revenue.167 A federal excise tax on sugary bever-
ages passed in Mexico led to a 12% reduction in purchases, 
with the greatest reductions seen in lower socioeconomic 
groups.167a The Congressional Budget Office estimates that 
a tax of 3 cents per 12-oz drink would raise just under $5 
billion a year, which could be spent on obesity prevention 
programs or education campaigns.168
2. Remove SSBs from all restaurant children’s meals.
Because children consume about a third of their calories from 
away-from-home meals and studies show that restaurant foods 
typically contribute higher calories and less nutritional value 
than foods prepared at home,169 this policy priority has the 
potential to affect the quality of children’s diets. In 1 study, 
implementing healthy children’s meals increased milk and 
juice consumption and decreased orders of soda.170 In a fol-
low-up study, changes were sustainable.171 Other initiatives 
have shown similar success.172,173 However, few such interven-
tion studies have been published.
3. Remove taxes levied on bottled and vended drinking water.
This is such a new policy approach that there is not yet any 
evidence on CVH impact. Policy makers may be reluctant to 
consider this initiative because of the loss of revenue; how-
ever, future research is needed to determine whether any sub-
sequent health benefit outweighs revenue losses.
4. Ensure that water is free, clean, and accessible in the 
school and community setting.
To assess the strength of the evidence to date on ensuring access 
to clean water at the community level, the AHA policy research 
staff used the QuIC Evidence Assessment method as developed 
by the CDC, which uses the best available evidence for a given 
component of a policy to classify it on a 4-part grid: Evidence 
Quality and Public Health Impact are represented as the 2 axes, 
and the categories of emerging, promising impact, promis-
ing quality, and best represent in turn the 4 quadrants.*†‡ To 
determine the best available evidence for this policy, the staff 
searched PubMed, MEDLINE, Google Scholar, and Cochrane 
for empirical and nonempirical research to date with the fol-
lowing search terms: public water access, free water access, 
clean water access, public water fountains, public water access 
health, public parks water, public water availability, and free 
community water access. The evidence gained from the cited 
research was used to assess potential policy impact.174–185 For 
this policy, the Evidence Quality Score was 28 and the Public 
Health Impact Score was 15. This result placed the impact of 
ensuring clean water access at the community level in the cat-
egory of promising quality.
5. Support SSB warning labels.
Because this is a new initiative, there is a lack of scientific 
evidence specifically related to warning labels on SSBs. Some 
public health advocates and policy makers have drawn a com-
parison to warning labels on tobacco and alcohol products, 
for which there is abundant literature evaluating effectiveness. 
From this literature, evidence suggests that a health warning 
label is potentially a prominent source of health information 
and an effective tool for increasing awareness, changing atti-
tudes, and changing behavior.186–188 However, the impact of a 
health warning label depends on its design and size and the 
social norms surrounding the underlying behavior.189 Smaller 
textual labels do not have as strong an impact as larger labels 
or graphic labels.186,189 Graphic labels have a greater impact 
than text-only labels, and graphic labels that elicit strong emo-
tional responses are most effective.189 Much more research 
is needed on the efficacy of SSB-specific warning labels, 
the impact on consumer purchasing, industry response, and 
whether there is a shift to drinking diet beverages or healthy 
choices such as water.
Sodium
The deleterious health effects of excess dietary sodium in 
children, adolescents, and adults are extensively docu-
mented, and the benefits of reduced sodium intake are like-
wise well known. Excess intake of sodium causes elevated 
BP, a major risk factor for CVD, stroke, and kidney dis-
ease.190 Independently of its effects on BP, excess sodium 
has adverse effects on the heart, kidneys, and arteries.191 The 
research supports the AHA’s advocacy of population-wide 
*The Evidence Quality Score assesses the level of evidence quality for 
the overall evidence base on the basis of the study types used, the sources 
providing the evidence, and the amount of evidence derived from practice, 
theory, and research. This score ranges from 1 to 40, with 40 being the 
highest level of quality.
†The Public Health Impact Score assesses the level of evidence of 
public health impact related to the use of the component, as suggested 
by the overall evidence base. Impact level is based on actual or suggested 
outcomes related to health, equity, efficiency, and transferability. This 
score ranges from 1 to 40, with 40 being the highest level of impact.
‡Component evidence categories include the following: Best, the 
components of which have higher levels (a score >20) of both quality and 
impact; Promising Quality, the components of which have higher levels of 
quality but lower levels of impact; Promising Impact, the components of 
which have higher levels of impact but lower levels of quality; and Emerging, 
the components of which have lower levels of both quality and impact.
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sodium reduction efforts, including support of the Million 
Hearts Initiative and its strategy to reduce population-level 
sodium intake through community-level programs. The 
AHA recommends a sodium upper limit of 1500 mg/d. 
Other national (US Department of Agriculture, Institute 
of Medicine)107,192 and global (World Health Organization) 
agencies193 similarly recommend reducing daily sodium 
intake but differ on specific goals, ranging from 1200 to 
2300 mg/d. Nationally representative data from NHANES 
find highly excessive intakes of sodium in US children, ado-
lescents, and adults.194 Current estimated sodium intakes in 
US adults approximate 3400 mg/d exclusive of table-added 
salt and have not improved since the mid-1990s. Average 
sodium intakes for children 2 to 5, 8 to 12, and 13 to 18 years 
of age approximate 2300, 3300, and 3400 mg/d, respec-
tively.194 Of note, >75% of Americans’ sodium intake comes 
from processed foods, which are also often calorie dense.195 
Although behavioral interventions help individuals reduce 
sodium intake, these approaches have not been successful in 
decreasing population-wide sodium intake.196,197 Availability 
of and access to affordable healthy (reduced sodium) foods 
are central to population-wide efforts. Environmental and 
policy approaches are needed to create optimal food envi-
ronments for all Americans.
Several current AHA policy priorities focus on reducing 
sodium in the US food supply. The AHA supports the inclu-
sion of sodium consumption standards in school nutrition 
programs, food marketed to children and youth, and foods 
purchased by employers and government programs. The AHA 
also advocates for improved food labeling and menu informa-
tion to help individuals understand how much sodium they 
are consuming. In addition, multisector efforts involve food 
manufacturers, food processors, and restaurant industries to 
reduce population-level dietary sodium intake. These efforts 
include working with government agencies and the food 
industry to implement sodium reduction via procurement pol-
icies and lower sodium standards in government-subsidized 
food programs.
1. Support FDA voluntary standards for sodium reduction 
and revision of the Nutrition Facts Panel.
In modeling exercises and intervention research across a 
number of countries, researchers strongly suggest that popu-
lation-based strategies of sodium reduction are cost-effective 
and potentially impactful in terms of CVD and total mortal-
ity.191,198,199 Because the current levels of dietary sodium are 
so high, a combination of personal/clinical interventions, 
community-based changes, and food industry reforms (eg, 
reduced sodium in bread) is needed to achieve estimated 
potential population benefits.200 Changes in the supply of 
dietary sodium in the macroenvironment, especially col-
laborations with and regulatory changes in the food industry, 
will have the largest impact on public health.199,201–203 If the 
US population moved to an average sodium intake of 1500 
mg/d, there would be a 25.6% decrease in high BP (HBP) and 
a $26.2 billion savings in annual healthcare spending.203 Even 
getting the US population to 2300 mg has been estimated to 
save $18 billion in healthcare costs annually and could lead to 
overall savings from reduced CVD morbidity and mortality of 
$32 billion annually.204
Other AHA Diet Metrics (Not Prioritized Although Addressed 
Within Policy Approaches to the Overall Dietary Pattern)
1. Fish/seafood.
The cardiovascular benefits of fish/seafood and marine 
omega-3 fatty acids have been the topic of extensive 
reviews.205–207 Dietary (not supplemental) fish or fish oil con-
sumption reduces CHD mortality, including fatal myocardial 
infarction and sudden cardiac death, in populations with and 
without established CVD.207 Fish consumption (1–2 servings 
per week) reduced the risk of coronary death by 36% and total 
mortality by 17% in a pooled analysis of prospective stud-
ies and randomized trials.206 The AHA has provided guidance 
for almost 2 decades for the consumption of fish/seafood and 
marine omega-3 fatty acids.106 From a policy perspective, the 
AHA addresses seafood consumption through broader sys-
temic approaches to diet quality, including nutrition standards 
for schools and workplaces and in government feeding pro-
grams. In addition, programs are needed that make fish/sea-
food widely available at an affordable price.
2. Whole grains.
As summarized by the 2015 US Dietary Guidelines Advisory 
Committee report, whole grains are those “foods made from 
the entire grain seed, usually called the kernel, which con-
sists of the bran, germ and endosperm. If the kernel has been 
cracked, crushed or flaked, it must retain nearly the same 
relative proportions of bran, germ and endosperm as the 
original grain in order to be called whole grain.”112 The vast 
majority of the US population consumes less than the rec-
ommended amounts of whole grains but instead has a high 
intake of refined grains, including white flour–based products, 
white rice, and degermed cornmeal. Detrimental aspects of 
refined grains, including added fats, sugar, and sodium, often 
accompany these foods; however, because they are typically 
enriched with folic acid (white flour), iron, and B vitamins, 
inclusion of some of these foods can benefit overall nutritional 
status.112 Only ≈19% of the US population, including all ages 
and both sexes, meet the recommendation for limited intake 
of refined grains; the vast majority (>70%) exceed this intake, 
especially boys and girls 4 to 8 years of age and girls 9 to 13 
years of age.112
On the other hand, recommended amounts of dietary 
fiber are underconsumed by the majority of the population. 
Dietary fiber is derived not only from whole grains but also 
from fruits, vegetables, beans, peas, legumes, nuts, and other 
plant-based foods. The 2015 US Dietary Guidelines Advisory 
Committee reported less than the recommended intake of all 
these foods, and consequently inadequate dietary fiber intake, 
by the majority of the population. Dietary fiber is associated 
with reduced risk of CVD, including lower BP and low-den-
sity lipoprotein cholesterol (LDL-C). Recommended intake is 
14 g fiber/1000 kcal or 25 g per 2000-kcal diet.107
Systemic policy approaches such as nutrition standards in 
schools and early child care, as well as nutrition standards for 
government food purchasing in feeding programs or for food 
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service, can increase whole grains in foods that are offered, 
sold, and served.
Total Cholesterol (Not Prioritized, Although Implied Within 
Physical Activity and Dietary Policies)
Blood cholesterol has a well-established causal role in the 
development of atherosclerosis and clinical cardiovascular 
events.208–211 Lifetime exposure to elevated total cholesterol 
and LDL-C levels constitutes a major factor in the risk of car-
diovascular events.2,212–214
Writers of the “2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol to Reduce Atherosclerotic 
Cardiovascular Risk in Adults” found that statin therapy 
reduced atherosclerotic CVD (ASCVD) risk across the spec-
trum of LDL-C levels and recommended initiating statin ther-
apy at 40 to 75 years of age on the basis of the level of ASCVD 
risk in those with LDL-C >190 mg/dL.215 Earlier cholesterol 
guidelines that relied on LDL-C treatment thresholds perform 
less well than the 2013 ACC/AHA cholesterol guideline in 
identifying high-risk patients expected to benefit from statin 
therapy.216–218
The 2013 ACC/AHA guideline recommends treating all 
individuals 40 to 75 years of age with LDL-C ≥190 mg/dL 
or calculated risk >7.5% over 10 years, patients with clini-
cal ASCVD, and those with diabetes mellitus with statin 
therapy. Additional LDL-C–lowering nonstatin therapy is 
also recommended, if needed, to reduce both short-term and 
lifetime risk of ASCVD.215 LDL-C ≥190 mg/dL resulting 
from genetic causes is a strong risk factor for the premature 
onset of ASCVD. Healthy lifestyle habits are recommended 
for all individuals with and without genetic hypercholester-
olemia. Avoidance of smoking and control of other risk fac-
tors are essential. For LDL-C ≥190 mg/dL, drug treatment 
to lower LDL-C should be started as soon as possible in 
adults 40 to 75 years of age.215
The “Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Children and 
Adolescents: Summary Report” by the National Heart, Lung, 
and Blood Institute Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Children and 
Adolescents recommends that screening for genetic causes of 
hypercholesterolemia should begin by 2 years of age if there 
is a family history of premature ASCVD, known parental his-
tory of hypercholesterolemia, total cholesterol >240 mg/dL, 
or presence of diabetes mellitus, hypertension, smoking, BMI 
≥95th percentile for age, or a moderate- or high-risk medical 
condition.220 Universal lipid screening should begin at 9 to 11 
years of age and be repeated at 17 to 21 years. Once a child 
or parent with LDL-C ≥190 mg/dL is found, effort should be 
undertaken to screen relatives for elevated cholesterol levels 
(cascade screening).222
For adults, according to the 2013 ACC/AHA guidelines, 
assessment of ASCVD risk should begin by 21 years of age 
and should be repeated every 4 to 6 years if statin therapy is not 
started.212,215 This screening provides the opportunity to iden-
tify individuals with LDL-C ≥190 mg/dL, to assess 10-year 
and lifetime risk of ASCVD, and to counsel on healthy life-
style habits and control of risk factors.
Once it has been determined that a patient has the poten-
tial for a net benefit from statin therapy and statin therapy is 
initiated, the 2013 ACC/AHA guideline recommends regular 
monitoring through patient-clinician discussion and mea-
surement of fasting lipids to assess long-term adherence to 
lifestyle and drug therapy.215 Evidence shows that treatment 
initiation and long-term adherence to statin therapy are sub-
optimal even among high-risk patients.223,224 Effective, multi-
factorial programs to address nonadherence exist but have yet 
to be broadly implemented.225 Components of these programs 
include improving understanding of the treatments, provid-
ing counseling and accountability, ensuring availability of 
strategies and tools to encourage patient self-monitoring, and 
increasing the affordability of medications.
Screening, statin treatment, cholesterol control, and long-
term adherence are less successful in high-risk women and 
in nonwhite patients than among others.224,226–230 Lower socio-
economic status, limited healthcare access, enrollment in 
lower-performing health plans, and dependence on Spanish 
language appear to account for some of these disparities in the 
health care of blacks and Hispanics.227–229
Policies that improve access to prevention and treatment 
of hypercholesterolemia include those discussed above under 
healthy diet and physical activity, as well as those relating to 
healthcare access, quality, and affordability. The latter aspects 
include expanding coverage for groups not adequately cov-
ered by the ACA, reimbursement and minimal copays for pre-
ventive services, and the AHA’s partnership with the Million 
Hearts Initiative.
Blood Pressure
HBP is a major risk factor for CVD and stroke.231 In 2010, the 
overall death rate (age adjusted) for HBP was 18.8 per 100 000 
population. Death rates were 17.2 per 100 000 for white men, 
15.0 per 100 000 for white women, 50.2 per 100 000 for black 
men, and 37.1 per 100 000 for black women.232 The estimated 
combined direct and indirect cost of HBP in 2010 was US 
$46.4 billion (unpublished National Heart, Lung, and Blood 
Institute tabulation of Medical Expenditure Panel Survey 
data). Although recent discussions have focused on the details 
of BP control targets and the relevant evidence,233,234 it is well 
established from clinical and community trials that control-
ling HBP can reduce cardiovascular morbidity and mortality, 
reduce stroke incidence, slow the progression of kidney dis-
ease, and lower overall mortality.235 The AHA considers an 
ideal BP to be a systolic BP <120 mm Hg and diastolic BP 
<80 mm Hg.
The AHA’s BP control policy focuses on 4 general cat-
egories of evidence-based strategies, as well as supporting the 
BP control targets of the Million Hearts Initiative. Effective 
interventions target healthcare policy makers, insurers, phar-
maceutical concerns, healthcare providers, workplaces, and 
patients. Current policy targets are the following.
Increase Access to Appropriate Treatments
The AHA has adopted policy goals related to expanding 
and protecting access to affordable, adequate, and transpar-
ent insurance coverage; however, the relationship between 
insurance status and health outcomes is inconsistent. There 
is considerable uncertainty about a population-wide causal 
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relationship between insurance coverage and health status, 
given multiple contributing factors.236 There is some evi-
dence of increased mortality among those without insur-
ance237 and relatively lower mortality in populations with 
greater insurance coverage rates than in those with lower 
coverage rates.238 There is also evidence that insurance cov-
erage is correlated with health indicators other than mortal-
ity. In 1 study, those without health insurance had poorer 
short-term outcomes after the diagnosis of a chronic condi-
tion than those with insurance.239 In another study, research-
ers documented significantly higher rates of self-reported 
excellent or very good health in populations with greater 
compared with lower insurance coverage rates.238 Insurance 
coverage can improve the health of some population sub-
groups, some of which have been the targets of coverage 
expansion policies.236 The AHA supports expanded insur-
ance coverage for populations not adequately covered by the 
ACA (eg, those in states that have not expanded Medicaid 
eligibility). There is evidence that increased rates of insur-
ance coverage analogous to that afforded by the ACA are 
related to lower mortality.238 The AHA supports policies 
that seek to eliminate health insurance disparities that affect 
minorities. In states that have not expanded Medicaid, 40% 
of uninsured blacks who qualify are left without coverage 
compared with 24% of qualified Hispanics and 29% of quali-
fied whites.240 Minority Medicare beneficiaries are less likely 
to receive Part D prescription drug benefits than whites, with 
the highest disparity affecting Spanish-preferring Latinos.241 
The AHA supports reimbursement and minimal copays for 
preventive services.242
The impact of expanded, affordable insurance and 
improved access to health care on HBP and its sequelae is 
uncertain. If increased coverage allowed 17 million more 
Americans to successfully control their HBP, it is estimated 
that 146 970 BP-related heart attacks and 51 200 strokes could 
be prevented each year with $2.92 billion in cost savings.243
Ensure Continued Funding and Implementation of the 
Million Hearts Initiative
The AHA developed or supported public health programs tar-
geting HBP control and is committed to policies that ensure 
their continued funding and implementation, including the 
US Department of Health and Human Services Million 
Hearts Initiative. This program seeks to prevent 1 million 
heart attacks and strokes by 2017 and includes several goals 
related to BP control, including increasing the percentage of 
people with controlled HBP; better identifying people with 
HBP who are not yet diagnosed; enhancing individuals’ abil-
ity to control their HBP; increasing measurement and report-
ing of HBP control by healthcare systems, professionals, 
communities, and others; and decreasing the nation’s sodium 
intake. Some of the activities to support these objectives are 
community efforts to reduce sodium in the food supply, pub-
lic education campaigns to help Americans make healthy 
food choices and decrease tobacco use, and use of health 
information technology and quality improvement initiatives 
to standardize and improve the delivery of care for HBP. The 
overall impact of the Million Hearts Initiative remains to be 
determined.
Monitor Drugs and Devices, Including Research on the 
Approval Process and Timeliness, Integration of Innovations 
Into Delivery Systems of Care, and Medication Adherence
The AHA monitors issues related to drugs and devices used 
to treat HBP. Poor medication adherence is a significant issue 
in the United States, where it results in 33% to 69% of med-
ication-related hospital admissions at a cost of ≈$100 billion 
a year.244 An estimated 46 000 deaths could be avoided each 
year if 70% of patients with HBP received the treatment they 
need.245 The risk of hospitalization, rehospitalization, and pre-
mature death among patients with HBP is >5 times higher 
with poor adherence than among those who adhere to their 
treatment.246 Further policy development is needed to address 
medication adherence more effectively.
Drug formularies dictate particular pharmaceuticals that 
may be dispensed or reimbursed within a given system of care. 
Therefore, formularies influence prescribing patterns, and 
changes to formularies can potentially affect patient care. In 1 
study, insurance-driven formulary changes resulted in adverse 
medical outcomes, decreased satisfaction with health care, 
and an increased burden on physician practice,247 especially 
under government insurance programs. Formulary changes 
involving hypertension medications were among the most 
problematic.
As of 2013, nearly 90% of the US population owns some 
sort of mobile device.248 Use of mobile BP monitors and medi-
cation reminders reduces hypertension rates.249–252 However, 
long-term efficacy of such devices and optimal strategies for 
their integration into delivery systems of care, including reim-
bursement strategies, are still to be determined.
Integrate the AHA’s BP Algorithm Into Delivery  
Systems of Care
A recent science advisory from the AHA in conjunction with 
the ACC and the CDC underscored the value of treatment algo-
rithms for effective HBP control.253,254 Results from the land-
mark Systolic Blood Pressure Intervention Trial (SPRINT)255 
will continue to drive policy toward HBP prevention, treat-
ment, and control. SPRINT found 43% fewer CVD-related 
deaths in patients who were treated with a target systolic BP of 
120 mm Hg instead of the 140 mm Hg that has long been con-
sidered the appropriate target. Additionally, there were 27% 
fewer deaths resulting from any cause among patients in the 
lower BP target group; the rate of fatal or nonfatal heart attack, 
acute coronary syndrome, stroke, or heart failure was lower by 
25%; and there were 38% fewer cases of heart failure in the 
more aggressively treated group. There were, however, higher 
rates of acute kidney injury and other adverse effects, offset-
ting these benefits to a corresponding degree. Further policy 
work will support efforts that make integration of any revised 
treatment goals a standard of care within the US healthcare 
delivery system.
Fasting Plasma Glucose (Not Prioritized, Although Implied 
Within Dietary and Physical Activity Policies)
Fasting plasma glucose is a CVH factor that serves as an indi-
cator of diabetic and metabolic health status. Ideal (<100 mg/
dL), intermediate (100–125 mg/dL or treated to goal), and 
poor (≥126 mg/dL) levels correspond to previously defined 
nondiabetic, prediabetic, and diabetic status, respectively.1 
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An AHA/American Diabetes Association scientific statement 
notes that glycated hemoglobin A1c is the preferred diagnostic 
test for type 2 diabetes mellitus, with levels of <5.7%, 5.7% to 
6.4%, and ≥6.5% corresponding to the same respective levels 
of risk as fasting plasma glucose.256 The statement also empha-
sizes the importance of management of concomitant vascular 
risk factors for cardiovascular prevention in individuals with 
diabetes mellitus. Another AHA scientific statement addresses 
the management of cardiovascular risk factors in youth with 
diabetes mellitus, also focusing on strategies for reducing the 
excess risk.257
The prevalence of ideal fasting plasma glucose based on 
NHANES data from 2011 to 2012 was 85.3% at 12 to 19 years 
of age, 74.7% at 20 to 39 years of age, 52.4% at 40 to 59 
years of age, and 31.3% at ≥60 years of age.14 The progressive 
development of prediabetes and diabetes mellitus from adoles-
cence throughout adulthood is similar to other CVH metrics 
(ie, BP and cholesterol) in which CVH declines throughout 
the life course. The prevalence of prediabetes and diabetes 
mellitus increased from 9% to 23% between 1999 and 2007 
among those 12 to 19 years of age, equivalent to a decline in 
ideal fasting blood glucose from 91% to 77% over this 8-year 
period.18 Promotion and preservation of ideal fasting plasma 
glucose from childhood appears to be an important strategy to 
improve the CVH of the population.
On the basis of NHANES data for 2009 to 2012, among 
adults, the estimated prevalence of diabetes mellitus in the 
United States was 21 100 000 physician-diagnosed cases 
(8.5%), 8 100 000 undiagnosed cases (3.3%), and 80 800 000 
cases of prediabetes (35.3%) in the United States.14 Non-
Hispanic blacks and Hispanics have a substantially greater 
prevalence of prediabetes than whites, reflecting an important 
race/ethnic CVH disparity. Approximately 600 000 hospital-
izations and healthcare costs of $245 billion were attributed to 
diabetes mellitus in 2012.259
Type 2 diabetes mellitus is preventable. For example, the 
Diabetes Prevention Program found reductions in diabetes 
mellitus in overweight and obese patients treated with either 
lifestyle intervention or metformin.260 Lifestyle intervention 
was more effective, reducing the incidence of diabetes mel-
litus by 58%. Evidence that healthy diet, adequate physical 
activity, and avoidance of unwanted weight gain are critical 
for diabetes mellitus prevention implies that maintenance of 
healthy blood glucose may be achieved through the policies 
and practices addressing these behaviors that are currently on 
the AHA policy agenda. The same targets underlie manage-
ment of already-established diabetes mellitus in children and 
adults.256,257 For those with diabetes mellitus, cardiovascular 
events and stroke can be lessened in diabetics with lipid-low-
ering therapy and tight BP control.256
CVD and Stroke Mortality
Systems of Care/Acute Care
Improve Care for ST-Segment–Elevation Myocardial 
Infarction, Stroke, Emergency Medical Services, and Out-of-
Hospital Cardiac Arrest
Supporting and expanding comprehensive, coordinated sys-
tems of care for acute myocardial infarction and stroke is of 
vital importance. It is critical that the AHA, together with 
other organizations, continue to identify, define, and imple-
ment exemplary local, regional, and national systems of care 
for acute cardiovascular events and stroke. Providing com-
munities, emergency medical services agencies, clinicians, 
and health systems with proven tools, algorithms, strategies, 
programs, and other best practices, along with expertise and 
technical assistance for implementing and improving systems 
of care, is essential. Coordinated systems of care can make 
significant contributions to improving the care of patients 
with acute ST-segment–elevation myocardial infarction and 
for reducing the devastating effects of stroke.9
It is estimated that nearly half of Americans live >1 hour 
away from a primary stroke center, so telemedicine can help 
to support an effective stroke care system.261 The use of tele-
medicine is very effective in the evaluation and treatment 
of acute stroke, including significantly increasing the use of 
appropriate treatment in rural and neurologically underserved 
areas.262 Preliminary studies using real-time telemedicine 
links in emergency medical services vehicles allow medical 
personnel at a primary stroke center or comprehensive stroke 
center to evaluate the patient and assist in making emergent 
triage decisions.263 Telemedicine is also useful for providing 
stroke consultation for patients with a subacute stroke and 
patients already hospitalized with stroke or transient isch-
emic attack, supplementing existing stroke care processes, 
designing appropriate secondary stroke prevention regimens, 
determining rehabilitative needs, and planning disposition 
and reintegration into community and home environments for 
poststroke care.10,264 An AHA advocacy priority continues to 
be expanding policies to allow the greater use of telemedicine 
services such as interstate licensing agreements and expanded 
coverage beyond rural or underserved areas.
Reform Payment and Delivery Systems
The AHA has convened an expert panel to inform its efforts 
on this important area of policy development, assessing the 
evidence base as it continues to evolve as different payment 
and delivery models are tried in the healthcare marketplace.
Explore Evidence-Based Opportunities for Integration of 
Health Information Technology and Mobile Technology in 
Delivery Systems of Care and Support Clinical Registries
Improving care coordination models, ensuring optimal use of 
health information technology, and exploring evidence-based 
opportunities for the integration of mobile health technologies 
into delivery systems of care are also important priorities with 
an evolving evidence base. The Agency for Health Research 
and Quality reports that clinical decision support, the provi-
sion of clinical knowledge and patient-specific information 
to help clinicians and patients make decisions that enhance 
patient care, has potential to improve quality and reduce costs 
by increasing adherence to evidence-based practices.265 These 
tools may enhance the use of evidence-based therapies for pri-
mary and secondary prevention in every care setting.
Improve the Quality and Comprehensiveness of Healthcare 
Data Reporting and Increase the Use of Clinical Registries
Clinical registries and performance improvement systems 
play a vital role in measuring and improving the quality of 
cardiovascular and stroke care delivered in the in-hospital, 
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post-hospital transition, and outpatient settings. Use of per-
formance improvement registries is associated with improve-
ments in quality of care and clinical outcomes over time.266 For 
example, as a result of the Get With The Guidelines (GWTG)–
Stroke program, which uses a registry to collect and feed back 
information, participating hospitals had improvement in their 
adherence to stroke performance measures.267 Additionally, 
the AHA has supported the use of state-based registries to 
measure and track acute stroke care and to improve stroke care 
quality. One example is support of appropriations both for the 
CDC’s Paul Coverdell National Acute Stroke Registry and for 
the CDC’s work to provide funding and technical assistance to 
states to develop, implement, and enhance data collection sys-
tems for acute stroke. Those data can be used to guide qual-
ity improvement programs for acute stroke care, benefiting 
patients.268 CDC estimates that from 2005 through mid-2015, 
>550 000 patients have benefited from hospital participation in 
the Paul Coverdell National Acute Stroke Registry program.269
Clinical registries also support quality and safety evalua-
tion by monitoring adverse events related to particular therapies, 
drugs, or devices270,271 and examining provider adherence to 
safety protocols and best practice guidelines.272 Data collected via 
a clinical registry can help to identify opportunities to improve 
care and catalyze systems changes on a national basis to pro-
mote more timely and effective care. National data have shown 
disparities in guideline-recommended timely administration of 
tissue-type plasminogen activator for acute ischemic stroke, with 
little change over 7 years. A national initiative, Target: Stroke, 
was organized to address this issue. As a result, there was marked 
improvement in door-to-needle times for tissue-type plasmino-
gen activator administration, more eligible patients were treated, 
and substantial improvements in clinical outcomes were seen.267 
Data collected via a registry can also stimulate systems changes 
on a regional or statewide basis to promote a more comprehen-
sive and coordinated approach to care. Regional participation in 
quality improvement programs that use a clinical registry can 
help identify problems in the system of care so that corrections 
and improvements can be made. Greater participation in inno-
vative programs such as the AHA’s Heart 360, AHA/American 
Stroke Association’s GWTG program, and the AHA/American 
Diabetes Association/American Cancer Society Guideline 
Advantage Program should also be encouraged and incentivized.
Clinical registries are also an efficient way to collect infor-
mation on healthcare trends, to assess how elements of the 
healthcare system are functioning, and to better understand 
the prevalence and impact of disease. Clinical registries can be 
used to assess disease progression, to evaluate treatments, and 
to monitor treatment outcomes and adverse events.273,274 They 
can also evaluate trends in healthcare use and the provision of 
medically necessary care (including underuse, overuse, and 
misuse),275 monitor the impact of prevention efforts and public 
health awareness campaigns,276 analyze referral and diagnosis 
patterns, describe patient population demographics and pro-
vider characteristics, and track the incidence of health events 
and recurrent events.277
Clinical registries play an essential role in monitoring the 
healthcare needs of and the services used by patient popula-
tions often underrepresented in epidemiological studies and 
clinical trials, including racial and ethnic minorities, women,278 
the elderly,279 individuals with multiple comorbidities,280 and 
individuals with rare diseases. Using data from a clinical reg-
istry, researchers can identify and evaluate healthcare dispari-
ties within a patient population, examine underrepresented 
populations and their access to healthcare services, investigate 
disease progression and healthcare use in a particular sub-
populations, and evaluate treatment costs. Registries, as dem-
onstrated by the experiences of the GWTG–Coronary Artery 
Disease, GWTG–Heart Failure, and GWTG-Stroke registries, 
can help hospitals reduce disparities in care.266 Hospitals par-
ticipating in GWTG–Coronary Artery Disease, GWTG–Heart 
Failure, and GWTG-Stroke have improved care for black, 
Hispanic, and white patients equitably to reduce or eliminate 
disparities in care.280
Integrate the AHA’s Principles for Palliative Care Within 
Delivery of Care
Palliative care is patient- and family-centered care that 
improves life by anticipating, preventing, and treating suffering. 
Palliative care, with its primary focus on both relief of symp-
toms and supportive care, has the potential to alleviate patients’ 
and family caregivers’ distress, improve their overall quality 
of life, and foster well-being even as seriously ill patients live 
with illness burden. This is an expanding body of research that 
demonstrates that patients living with serious illness, including 
those with CVD and stroke, identify several elements of pal-
liative care among their top priority needs from the healthcare 
system such as improving pain and symptom management, 
avoiding inappropriate prolongation of dying, achieving a sense 
of control, and avoiding burdening others.281 Introducing early 
palliative care in the treatment of patients with metastatic non–
small-cell lung cancer extended mean survival, reduced depres-
sion, and led to better quality of life compared with patients 
who did not receive concurrent palliative care.282 Patients with 
chronic pulmonary disease or heart failure receiving palliative 
care had significantly better outcomes on self-management of 
illness, awareness of illness-related resources, and legal prepa-
ration for end of life. These patients also reported lower symp-
tom distress, greater vitality, better physical functioning, and 
higher self-rated health than randomized control subjects.283 
Individuals with CVD and stroke should have access to a well-
coordinated medical team to personalize care, to optimize qual-
ity of life, and to minimize suffering.
Ensure Implementation of Pulse Oximetry for Newborns
A recent policy goal is to increase the use of pulse oximetry 
to screen newborns before they are discharged from a birth-
ing facility to identify infants with critical congenital heart 
defects. Without screening, critical congenital heart defects 
in some newborns might not be recognized until later in 
life. Pulse oximetry screening can substantially reduce the 
postnatal diagnostic gap in critical congenital heart defects; 
false-positive results leading to unnecessary examinations 
of healthy newborns are rare.284 In 1 study, introducing pulse 
oximetry screening before discharge improved the total detec-
tion rate of critical congenital heart disease to 92%.285 This 
appears to be cost-neutral in the short term and may be cost-
effective in the long term as a result of both reduced need for 
preoperative neonatal intensive care and probable prevention 
of neurological morbidity.
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Postevent Rehabilitation
Increase Access to, Use of, and Reimbursement for Cardiac 
Rehabilitation and Devise New Models of Care
Cardiac rehabilitation (CR) is a multidisciplinary, comprehensive 
program designed to optimize a patient’s physical, psychologi-
cal, and social functioning, in addition to modifying cardiovas-
cular risk.286 It is currently approved by Medicare for patients 
with myocardial infarction; patients with angina; patients after 
percutaneous coronary intervention, coronary artery bypass 
graft surgery, valve surgery, and cardiac transplantation; and 
more recently, select patients with congestive heart failure.13,287 
In patients with myocardial infarction, there is a 26% reduction 
in all-cause mortality, a 36% reduction in cardiac mortality, and 
a reduction in reinfarction with exercise-based CR.288 Despite 
these impressive benefits, it is estimated that <30% of eligible 
patients are referred and participate in the program.289 Only 
some 14% of Medicare patients hospitalized for acute myocar-
dial infarction and 31% of patients who undergo coronary artery 
bypass graft surgery actually use CR.290
There are several reasons for poor referral and use of CR. 
Systems-level factors contribute: A lack of automated and 
standardized methods of identifying appropriate patients and 
initiating referrals characterizes facilities with low CR use.291 
Patients commonly do not understand the benefits of the pro-
gram, particularly if they are not educated during the early 
inpatient period by the healthcare team.292 Lack of insurance 
coverage is a major barrier for participation; insured patients 
are almost 3 times as likely to be referred as the uninsured.293 
Those in rural areas are less likely to participate, partly as a 
result of the limited availability of nearby facilities, given the 
travel distance often required on a repetitive basis for contin-
ued participation.
Lower CR referral and participation rates dispropor-
tionately affect women, ethnic minorities, older individuals, 
and those of lower socioeconomic status.293,294 Not only are 
women referred less commonly than men, but they are given 
weaker recommendations for participation,296 possibly as a 
result of the perception that women may benefit less despite 
evidence to the contrary. Referral rates for nonwhites are also 
lower than those for whites, even after accounting for socio-
economic and insurance status.297,298 Such disparities are par-
ticularly relevant for blacks because of a higher risk factor 
burden and higher long-term CVD mortality rates.299 Patients 
of low socioeconomic status may be less able to miss work or 
to have the means to travel to rehabilitation centers, in addi-
tion to being underinsured and sensitive to copayment costs.128
Several programs and policies have the potential to mark-
edly improve CR referral and participation rates and to affect 
disparities in attendance.128 No single referral strategy but 
rather the combined approach of systematic procedures (ie, 
order sets and automated processes) plus personal liaison 
(ie, bedside provision of information by healthcare provider) 
provides the greatest impact.300 Hospital-based interventions 
that enable automatic electronic referrals such as the AHA’s 
GWTG program significantly improved referral rates.301,302 
Compared with standard referral methods, strategies that 
involve care coordination between patient, referring physi-
cian, and the CR team led to an increase in CR enrollment 
from ≈30% to 70%.130 In addition, programs designed to 
coordinate transfer of care between hospital and CR resulted 
in 18% higher CR use rate.303 Of note, automated strategies 
can help minimize disparities by ensuring nearly universal 
referral of patients, regardless of demographic or socioeco-
nomic status.304 The greater adoption of electronic health 
records and implementation of their meaningful use through 
the Health Information Technology for Economic and Clinical 
Health Act have the potential to significantly enhance auto-
mated referral processes for CR. Although CR referral is a 
performance measure and a quality metric in ACC/AHA reg-
istries such as the Acute Coronary Treatment and Intervention 
Outcomes Network (ACTION),305 it is not currently one of the 
Centers for Medicare & Medicaid Services acute myocardial 
infarction core quality measures. Given the focus on public 
reporting of core measures and the ability of such reporting to 
change practice,306 CR referral should be included in this list.
Healthcare reform, including aspects of the ACA, can 
enhance participation in CR, first by increasing the overall 
number of insured. In addition, the essential health benefits, 
which are requirements for all health insurance plans offered 
to individuals or through the small-group market, contain cov-
erage for rehabilitation services, including CR. Efforts should 
be made to preserve this designation of CR and to eliminate or 
minimize copayments that can be a barrier to participation,307 
as has been done for other preventive services under the ACA. 
In 1 study, uninsured individuals were 71% less likely to 
adhere to CR compared with insured individuals, and copay-
ment was associated with a 41% lower likelihood of adher-
ence.135 The accountable care organization model supported 
by the ACA encourages shared savings through preventive 
care, including CR, and facilitates coordination of care with 
redundant providers ensuring appropriate referral.
Patients in rural settings, the elderly, and those with lower 
income may have barriers to center-based CR, including lack 
of nearby facilities and challenges with transportation and 
job constraints. Internet-based, home-based, and commu-
nity programs may be alternative models for outpatient CR. 
Home-based models are at least as effective as center-based 
interventions in promoting physical and psychological well-
being308 and in improving cardiovascular risk factors such as 
systolic BP, smoking cessation, cholesterol level, and depres-
sion.131,309,310 Providing CR for socially vulnerable patients 
with home visits by a cardiac nurse is associated with higher 
adherence.311 Such alternative approaches should not replace 
traditional center-based CR but can be used to engage the 
many patients who currently are unable to participate because 
of various barriers.
Increase Access to, Use of, and Reimbursement for  
Stroke Rehabilitation Services and Continue Development  
of Tele-Stroke Services and New Poststroke Therapies
The AHA/American Stroke Association has promoted stroke 
systems of care to improve outcomes by coordinating care 
across a comprehensive, diverse, longitudinal system from 
primordial prevention, primary prevention, emergency medi-
cal services, acute care, secondary prevention, rehabilitation, 
and return to the community.9,312 Organized inpatient stroke 
units with coordinated, multidisciplinary stroke-related evalu-
ation and services are one of the most effective strategies to 
improve poststroke outcomes. Stroke patients who are treated 
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in an organized inpatient stroke unit are more likely to be 
alive, independent, and living at home 1 year after stroke.313
 Most stroke units include access to early evaluations by 
rehabilitation and prompt physical therapy assessments. Many 
of the organized stroke units outside the United States also 
include multidisciplinary rehabilitation services as part of the 
stroke unit stay. One of the National Quality Forum–endorsed 
voluntary consensus standards for hospital care for primary 
stroke centers includes the proportion of patients with isch-
emic or hemorrhagic stroke who were assessed for rehabilita-
tion services.
Despite the increased number of certified primary and 
comprehensive stroke centers, there is inadequate use of both 
inpatient and outpatient rehabilitation among US stroke sur-
vivors. Each year in the United States, ≈795 000 people are 
affected by strokes, and that number is expected to surpass the 
1 million mark by 2050. It has been estimated that >60% of 
stroke survivors do not receive adequate rehabilitation, with 
as few as 20% of stroke patients being discharged to inpatient 
rehabilitation stays.314 The extent of stroke rehabilitation (SR) 
is often limited by restrictions or lack of sufficient coverage 
in health insurance plans. Moreover, rehabilitation use among 
stroke survivors varies across hospitals and geographic loca-
tions, although there is no conclusive evidence on racial-eth-
nic disparities.315,316 Among Veterans Affairs stroke patients, 
the odds of receiving rehabilitation were significantly higher 
for urban-residing patients, compared with rural-residing 
patients.317 A study in the northwestern United States found a 
striking gap between rural and urban hospitals in stroke care 
capacity, including rehabilitation therapies.
Although tele-stroke services emphasize increasing access 
to acute stroke care, there is a developing interest in improv-
ing rehabilitation access also through telemedicine strategies. 
Most poststroke telemedicine studies have been small prelimi-
nary evaluations of rehabilitation in adults; further research is 
needed.318 Enhancing access to inpatient and outpatient reha-
bilitation services needs to be prioritized. Studies are needed 
to assess the efficacy of innovative approaches to deliver SR, 
particularly in rural regions.319
The primary goals of SR are to prevent complications, to 
reduce impairments and disabilities, and to maximize patients’ 
ability to be independent in activities of daily living. Most 
stroke centers recommend initiating SR as soon as possible 
once the diagnosis of stroke is established and the patient is 
medically stable enough to have physical therapy. Effective 
rehabilitation interventions initiated early after stroke can 
enhance recovery and minimize functional disability.
Specific pharmacological and device treatments for SR 
and recovery have lagged behind acute treatment and preven-
tion. Research in stroke recovery medications and interventions 
has been prioritized in the most recent National Institute of 
Neurological Disorders and Stroke stroke recommendations and 
priorities that called for targeting the first 3 months after stroke 
to assess the impacts of various interventions and to determine 
the time course of recovery.320 Rehabilitation strategies could 
include stimulation, pharmacological agents, devices, stem 
cells, and combination therapies to accelerate recovery in the 
acute period after stroke. The established Stroke Trials Network 
of the National Institute of Neurological Disorders and Stroke 
has a specific stroke-recovery planning group to help develop 
further randomized trials to evaluate recovery interventions.
Despite the lack of proven drugs and devices to enhance 
stroke recovery, there is considerable evidence of the reha-
bilitation benefits of various poststroke therapies to improve 
motor skills such as walking, reach and grasp, speech and 
language, visual field loss, and hemi-inattention.321 Multiple 
randomized trials support the use of physical therapy inter-
ventions particularly “intensive, high-repetitive, task-oriented 
and task-specific training.”322 Moreover, tailored counseling 
alone or with tailored supervised exercise promotes long-term 
participation in physical activity and improved functional 
exercise capacity after stroke.323 There is growing interest in 
self-management interventions to enhance stroke recovery, 
but research is needed to assess the appropriate content and 
delivery of these interventions and to determine the accept-
ability and efficacy of self-management programs.324
SR should be started early, maintained for a longer period 
of time after stroke, and available for a wider spectrum of 
stroke patients. There is a clear need to increase referral to, 
use of, and adequate reimbursement for SR services, includ-
ing access to appropriate levels of poststroke physical ther-
apy, occupational therapy, and speech/language therapies. 
Increasing referral, use, and adequate reimbursement for SR 
will improve the outcomes of countless stroke survivors and 
be instrumental in achieving the AHA goal of reducing mor-
tality from stroke by 20% by 2020.
Discussion
Alignment of Current Policies With  
the 2020 Strategic Impact Goals
The present review documents the extensive policy portfolio 
adopted by the AHA over many years that is closely aligned 
with strategies and tactics to achieve the 2020 Strategic 
Impact Goals. Tables 5 and 6 present the main findings of 
this review and indicate the nature of these policy interven-
tions and evidence base for the policy when an authoritative 
evidence review, whether internal to the AHA or otherwise, 
was used. In Table 5, especially striking is the wealth of 
policies that address smoking, diet, and physical activity.
Although BMI has not been explicitly prioritized in the 
AHA policy process for separate consideration and therefore 
leaves a gap in the table, it would be expected that effective 
implementation of the policies on physical activity and diet 
would have direct consequences in improved BMI. Similarly, 
lack of explicit policies on increasing intakes of fish and fiber-
rich whole grains leaves gaps in the area of the healthy diet 
score. However, policies addressing the diet overall, that is, 
advocating a DASH-like dietary pattern or the US Dietary 
Guidelines Advisory Committee’s recommended pattern, 
include these areas. In terms of both BMI and these com-
ponents of the healthy diet score, it remains to be decided 
whether adding explicit policies would strengthen the port-
folio. It could be argued that lack of a specific policy risks 
lack of effective monitoring of trends and disparities in these 
metrics, favoring making the policy and its measurable out-
comes explicit.
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Tables 5 and 6 also indicate that some, although not all, 
policies specifically address children (<20 years of), adults 
(≥20 years of age), or both. This aspect is in some cases self-
evident (as in tobacco policies affecting youth) and in others 
implicit (as in finalizing voluntary FDA standards for reduc-
tion of sodium across all food and beverage categories, affect-
ing both children and adults as parts of the whole population). 
Given the general decline in CVH metrics from childhood 
into and through adulthood, the opportunity to preserve ideal 
CVH is greater in childhood. This is in contrast to the need to 
reverse already impaired CVH, more typically in adulthood. 
The distinction by age between target populations for differ-
ent strategies is of fundamental importance. Effective policy 
implementation requires clear specification of target age lev-
els, whether child or adult, and perhaps by narrower age cate-
gories among children as currently defined. Similarly, policies 
might be refined by targeting more distinct age-specific levels 
of the metrics or score, whether ideal, intermediate, or poor.
Table 6 presents AHA policies applicable to individuals 
with recognized CVD or stroke to reduce mortality from these 
causes. Further aims are to prevent recurrent events and to 
reduce cardiovascular morbidity. Policies addressing CR and 
SR not only will improve quality of life but also will reduce 
disability for survivors. The policies in Table 6 on systems 
of care, including acute response and acute care for cardio-
vascular and stroke events, and on postevent rehabilitation 
for those who survive represent secondary or tertiary preven-
tion, whereas those on the CVH metrics in Table 5 concern 
primordial and primary prevention. Attention to the 7 metrics 
to reduce the risk of recurrent cardiovascular or stroke events 
and death is an integral part of secondary prevention. Here 
too the metrics that remain ideal should be preserved and pro-
tected, and those that are intermediate or poor require reme-
dial intervention.
Although the AHA’s policies are discussed in this state-
ment in the context of the AHA 2020 Strategic Impact Goals 
and therefore in relation to the US population and healthcare 
system, the AHA has also been a key partner in the growing 
international advocacy efforts to reduce the burden of pre-
mature deaths from noncommunicable diseases. In 2011, the 
United Nations High-Level Meeting unanimously adopted 
a Political Declaration on the Prevention and Control of 
Noncommunicable Diseases.325
 CVD and stroke are the first 
and second leading causes of global mortality from noncom-
municable diseases. The World Health Organization adopted 
a global monitoring framework for noncommunicable dis-
eases and set multiple targets, including reduction of pre-
mature mortality from noncommunicable diseases by 25% 
by 2025.326 The World Health Organization set target levels 
for several risk factors, including reductions in BP, smoking, 
alcohol, sodium consumption, and physical inactivity and a 
halt to the rise in obesity and diabetes mellitus. Most of the 
AHA’s policies described in this statement are applicable to 
both the World Health Organization goals and the AHA inter-
national impact goal of reducing premature global mortality 
from CVD and stroke by 25% by 2025 and improving CVH 
in priority areas. Further support for this global policy frame-
work is provided by the World Heart Federation, whose 25 by 
25 program shares this CVD reduction goal.326a
Future Policy Development
Policies will continue to evolve as experience is gained with 
continuing implementation of the current policy portfo-
lio. Accumulating evidence will inform ongoing reviews of 
existing policies. The AHA policy research department will 
continually monitor these developments and initiate policy 
responses as appropriate. The AHA approach to evidence 
review described here will be further refined to guide this 
process.
Of particular note in this connection is AHA’s recent sci-
entific statement calling for attention to the social determi-
nants of health, “Social Determinants of Risk and Outcomes 
for Cardiovascular Disease”:
…[A]lthough we have traditionally considered CVD 
the consequence of certain modifiable and non-modi-
fiable physiological, lifestyle, and genetic risk factors, 
we must now broaden the focus to incorporate a third 
arm of risk, the social determinants of health. Failure 
to demonstrate awareness of this third dynamic will 
result in a growing burden of CVD, especially among 
those with the least means to engage in the healthcare 
system.225 
This statement thus anticipates a new dimension for 
policy development by the AHA, addressing elements of the 
Figure.
Thus, the scope of policy development would be widened 
to consider each of these determinants, that is, the social/
community context, health/health care, neighborhood/built 
environment, education, and economic resources/stability, all 
in the context of global, national, state, and local policy and 
practices. That statement presents evidence linking social fac-
tors with CVD risk and outcomes and strongly suggests that 
this awareness will substantially influence future development 
of the AHA policy portfolio.
Figure. American Heart Association determinants of health 
outcomes.
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Policy Research
Research needs in connection to policy to achieve AHA’s 
2020 and future strategic goals can be thought of in terms 
of 3 research functions: (1) for current policies, to evaluate 
their translation and implementation; (2) for development of 
new policies, to expand and strengthen the evidence base; 
and (3) for all policies, to evaluate their impact in terms of 
targeted improvements in population health. The first func-
tion calls for greatly expanded application of implementa-
tion science; the second, continued support of focused basic, 
clinical, and population research; and the third, significantly 
enhanced surveillance of population-level determinants 
of health, intervention effectiveness, and CVH- and CVD-
related outcomes at the national, state, and local levels. 
Special emphasis is needed on economic analyses, including 
cost-effectiveness, value of investment, and quality life-years 
saved, with overarching consideration of social determinants 
of health and of vulnerable populations. Research in these 3 
areas should include increased investment in modeling, with 
application of advanced analytic methods to expanding data 
sources as they become available. Each of these 3 research 
functions is discussed briefly, followed by an inventory of 
priority research needs specific to each metric for CVH and 
indicator of care and outcomes for reducing mortality from 
CVD and stroke.
1. Evaluating implementation of current policies.
Whether any particular policy is effective requires knowl-
edge about its implementation: its reach, fidelity to the 
original intent, and influence by particular circumstances. 
Success or failure of an intervention may result from various 
influential factors across diverse population groups and set-
tings, with lessons to be learned whatever the outcome. Such 
heterogeneity of outcomes is emphasized by Mozaffarian 
and others5 in their review of population approaches to diet, 
physical activity, and smoking. As they observed, knowl-
edge of influential factors can help to identify population 
settings where a particular intervention is effective or where 
adaptations are needed to make it so. Documentation is 
required to know how a given policy has been translated 
into action, what specific barriers or facilitators have been 
encountered in its implementation, and by what measures 
its impact has been evaluated. Much can be gained in future 
policy development and prioritization by ensuring sufficient 
commitment to this essential area of research, implementa-
tion science.
2. Strengthening evidence for new policies.
The ongoing research enterprise of the AHA and others, 
including especially the recently established Strategically 
Focused Research Networks program, ensures that new 
evidence and updated evidence reviews related to strategic 
goals will continue to accrue. In addition to the specific top-
ics listed in Tables 7 and 8, several generic issues in future 
research deserve consideration. For example, Mozaffarian 
and others5 point to the need for studies of multicomponent 
intervention strategies to disentangle their effects, financial 
and economic factors at the levels of both personal behaviors 
and health system operations, and better understanding of 
the impact of community environments on health behav-
iors, including standardization of research methods. They 
also call for greater investment in longitudinal rather than 
cross-sectional studies to enable inferences about causal 
sequences and long-term sustainability of interventions and 
favorable outcomes. Furthermore, Havranek and others, in 
discussing a research agenda on social determinants of car-
diovascular risks and outcomes, called especially for stud-
ies of interventions, programs, and policies in this area.225 
Several topic areas were identified, both methodological 
and substantive: standardization of social group categories; 
interactions among social factors and their links to CVH; 
nontraditional measures of social determinants indicating 
socioeconomic differences or racism; intergenerational 
transmission of social disadvantage; and psychosocial, 
behavioral, biological, and epigenetic aspects of social 
determinants and health.
3. Monitoring determinants of CVH and CVD outcomes.
When CVH metrics and CVD indicators were selected for 
the 2020 Strategic Impact Goals, several candidates were 
excluded or ranked as secondary metrics because of a lack 
of data from nationally representative population samples.1 
Accordingly, Lloyd-Jones and others2 strongly emphasized 
the need to strengthen data sources for monitoring and sur-
veillance of CVH and CVD in the United States. The AHA’s 
interest in monitoring the secondary metrics, and more ade-
quately tracking the primary ones in diverse populations and 
at all ages, will be better served as the needed data sources 
are identified or enhanced. Examples of target areas for 
improving data sources include national data on incidence, 
disease severity, 30-day case fatality, and recurrence rates 
for coronary events, stroke, heart failure, and sudden car-
diac arrest; GWTG or analogous metrics on quality of care 
for coronary artery disease, stroke, and heart failure; new 
metrics for psychosocial stress; indicators of the built envi-
ronment; metrics for cardiovascular symptom control; and 
individual-level exposure data on air quality and particulate 
matter. Methodological research is needed in several of these 
areas to develop tools for new and ongoing research on pop-
ulation-level CVH and CVD in support of policy evaluation 
and development.
Tables 7 and 8 present a matrix of priority areas for future 
policy research. Specific topics are arrayed in relation to both 
the metrics and indicators addressed in Tables 5 and 6 and the 
3 categories of policy research discussed above. The tables are 
not exhaustive but illustrate questions important for further 
policy development and the AHA’s ongoing strategic planning 
process.
In general, research on areas shown for translation and 
implementation of current policies would provide critical 
information on the effectiveness of advocacy for AHA’s policy 
portfolio. Topics listed under new policies identify examples 
for which new evidence could lead to refinement of existing 
policies or to altogether new policy priorities when gaps are 
found. Topics for study of population health impact include 
changes in prevalence of population-level exposures, health 
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Table 7. Topic-Specific Priority Areas for Future Policy Research: CVH
Health Behaviors  
and Factors
Current Policies: Translation  
and Implementation
New Policies: Expanding  
the Evidence Base
All Policies: Population  
Health Impact
Tobacco Address the cultural, social, and economic 
factors that promote, sustain, or discourage 
the use of e-cigarettes and other new 
tobacco products 
Determine the relative impacts of various 
taxation strategies on youth access to 
e-cigarettes, adult smokers’ use of these 
products, and industry response 
Assess the extent of including e-cigarettes 
in smoke-free air laws to decrease the use 
of e-cigarettes by adult smokers and youth 
access to and initiation of e-cigarette use
Test the efficacy of new tobacco 
products as cessation devices 
Determine whether new tobacco 
products serve as a gateway to 
conventional smoking and reinitiation  
by former smokers
Assess the extent and duration  
of dual use or use of multiple  
tobacco products 
Evaluate the impact of Tobacco 21 
purchasing laws on smoking prevalence, 
youth initiation, and youth access
Identify short- and long-term adverse 
health effects of e-cigarettes and other 
new tobacco products 
Assess the impact of marketing and 
communications on the prevalence 
of use of e-cigarettes and other new 
tobacco products 
Increase surveillance of e-cigarette use 
and other tobacco products 
Monitor effects of intentional or 
unintended use of other substances 
and medications in e-cigarette delivery 
devices and its impact
BMI Assess the extent of the use of BMI as a 
HEDIS measure on delivery of lifestyle/
behavioral counseling in the clinical 
environment and community settings
Assess the use of physical activity and 
dietary policies to affect BMI and other CVH 
metrics in specific age and demographic 
groups
Use the Behavioral Risk Factor 
Surveillance System and Youth Risk 
Behavioral Surveillance System to assess 
geographic variation in distributions and 
trends of BMI to aid in targeting state 
and local policy changes
Continue NHANES and other monitoring 
of population trends of BMI at all ages, 
beginning before school age, in large 
enough population samples for tracking 
of disparities and trends among  
multiple demographic groups,  
especially at early ages
Physical activity Determine how school wellness policies and 
early care and education standards are being 
implemented for promoting physical activity
Identify both barriers and promising 
strategies to increase the adoption  
of mixed-use zoning codes
Identify the most successful combinations 
of street-scale improvements to facilitate 
physical activity in diverse populations
Determine which policies are most effective  
in promoting physical activity in different 
settings
Conduct case studies and economic 
analyses to develop promising municipal 
policies for active transportation
Determine which shared-use policies 
involving schools are most efficacious 
and cost-effective
Evaluate the relative efficacy of  
multi-intervention strategies to  
promote physical activity in schools
Study the relation of park proximity  
and design to neighborhood levels  
of physical activity
Across all settings and policies, 
determine the impact of infrastructure 
and access on disparities in physical 
activity
Improve surveillance systems  
for levels of and disparities in physical 
activity and physical fitness across  
the US population to assess the impact  
of different policy approaches on 
population health for all major 
demographic groups
Healthy diet Gauge the extent of implementation of 
policies to improve access to affordable 
healthy foods, especially in vulnerable 
populations
Assess variations in the adoption of policies 
to promote the consumption of water and 
milk (and coffee/tea in adults) vs SSBs 
across different settings
Evaluate the processes of food policy 
implementation by setting and geographic 
region
Determine how differences in incentives/
disincentives within the Supplementation 
Nutrition Assistance Program influence 
consumer purchasing of healthy foods 
and beverages
Determine how pricing, taxation, and 
agricultural subsidies affect food and 
beverage consumption, health behaviors, 
and health outcomes
Develop RCTs targeting major 
food sources of sodium in specific 
demographic subgroups and devise 
interventions aimed at reducing intakes 
of these foods
On the basis of NHANES data, including 
“What We Eat in America,” monitor 
disparities and changes by age, sex, and 
ethnicity in dietary sources of sodium 
and trends in blood pressure, BMI, blood 
lipids, and glucose
Monitor food industry practices aimed 
to gradually reduce sodium content over 
time
Total cholesterol Assess the extent of expanded access 
to health care and whether changes are 
occurring in cholesterol management
Evaluate promising policy approaches to 
improve medication adherence
Measure the population health impact 
of integrating clinical guidelines into 
systems of healthcare delivery
Monitor disparities and changes in 
population distributions of blood lipids by 
sex and ethnicity at all ages
(Continued )
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behaviors, and health factors, the improvement of which is 
called for by the AHA 2020 Strategic Impact Goals. More 
robust monitoring and evaluation generally require enrich-
ment of population samples by age and ethnicity. This would 
enable more complete assessment of policy impact from the 
earliest years of life and across diverse populations by race/
ethnicity, geography, economic circumstances, and other 
determinants.
Conclusions
The AHA 2020 Strategic Impact Goals set bold targets of 
achieving a 20% improvement in CVH of all Americans 
while continuing to reduce CVD and stroke mortality by 
20%, both by the year 2020. The introduction of the concept 
of CVH with its 7 metrics has occasioned this special review 
of the AHA policy portfolio as it aligns with elements of the 
Strategic Impact Goals.
We have found current AHA policy to offer a comprehen-
sive array of policy guidance to action in both arenas: pro-
moting and preserving CVH and reducing CVD and stroke 
mortality. In the majority of cases, for a specified metric or 
indicator, there are referable policies supported by evidence 
reviews conducted by the AHA, an AHA/ACC collaboration, 
or other sources.
Table 8. Topic-Specific Priority Areas for Future Policy Research: CVD and Stroke Mortality
Health Behaviors  
and Factors
Current Policies: Translation  
and Implementation
 New Policies: Expanding  
the Evidence Base
All Policies: Population  
CVH Outcomes
Systems of care/acute 
care
Identify settings in which health information 
technology and mobile health technology are 
being deployed most successfully in the delivery 
of care and improving transitions of care
Monitor the uptake of policy on pulse 
oximetry screening for newborns and 
determinants of effective implementation
Compare the effectiveness and cost-
effectiveness of different advance care 
planning, palliative care, and hospice 
care systems
Determine how various care coordination 
models are affecting population health 
outcomes
Postevent rehabilitation Determine what specific policy approaches 
to enhance participation and adherence to 
CR programs are being used
Evaluate the extent of copayment elimination and 
systematic reporting of CR as a quality measure
Assess the impact that Centers for Medicare 
and Medicaid approval for CR coverage is 
having for stable patients with class II or III heart 
failure and an ejection fraction <35% on the 
basis of the results of the HF-ACTION Study,287 
as well as whether there will be specific 
impediments to enrollment of such patients
Pilot alternative delivery methods and 
their reimbursement to complement 
center-based care or to replace these 
programs for those who are unable to 
participate
Evaluate the effectiveness of innovative 
stroke rehabilitation programs using 
telemedicine and self-management 
programs
Assess the impact of better referral, 
use, and adherence to CR programs on 
population outcomes
CR indicates cardiac rehabilitation; CVD, cardiovascular disease; CVH, cardiovascular health; and HF-ACTION, Heart Failure and A Controlled Trial Investigating 
Outcomes of Exercise Training.
BP Assess the impact of reimbursement for 
home BP monitoring (equipment and clinical 
interpretation of results) on hypertension 
treatment, control, and medication 
adherence
Evaluate promising policy approaches to 
improve medication adherence
Determine the population health impact 
of integrating the AHA BP algorithm into 
systems of healthcare delivery 
Monitor disparities and changes in 
population distributions of BP by sex and 
ethnicity at all ages
Fasting plasma glucose Assess whether policies to improve health 
behaviors are being evaluated for their 
effectiveness in maintaining favorable levels 
of blood glucose and preventing type 2 
diabetes mellitus, especially in youth
Perform further studies in adults of 
the benefits and risks of alternative 
antihyperglycemic therapies, including 
bariatric surgery 
Expand studies of early life influences  
on the maintenance or loss of  
ideal fasting plasma glucose and 
interventions to promote and sustain 
ideal fasting plasma glucose across the 
population
Monitor disparities and changes in 
population distributions of blood glucose 
and prevalence of type 2 diabetes 
mellitus by sex and ethnicity at all ages
AHA indicates American Heart Association; BMI, body mass index; BP, blood pressure; CVH, cardiovascular health; e-cigarette, electronic cigarette; HEDIS, 
Healthcare Effectiveness Data and Information Set; NHANES, National Health and Nutrition Examination Survey; RCT, randomized, controlled trial; and SSB, sugar-
sweetened beverage.
Table 7. Continued
Health Behaviors  
and Factors
Current Policies: Translation  
and Implementation
New Policies: Expanding  
the Evidence Base
All Policies: Population  
Health Impact
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There are some instances in which further policy devel-
opment could add valuable support to the AHA’s efforts to 
achieve the 2020 goal: making policies explicit in situations 
in which, because of the existence of related policy, this has 
not been a priority (eg, BMI, fish, fiber); specifying policies 
that would guide different activities in the interest of children 
and adults; and incorporating established metrics for GWTG 
or similar measurable intermediate outcomes as indicators of 
acute or postevent care and health systems functioning.
This appreciation of the AHA policy portfolio invites fur-
ther assessment of the research portfolio and the potential for 
strengthening the science base for the AHA’s activities. How 
well are AHA’s policy priorities being realized at national, 
state, and local levels and for vulnerable populations? How 
well does ongoing science and evidence synthesis contribute 
to timely policy development? What is the impact of AHA 
policy, current or anticipated, on the measures of population 
CVH and CVD and stroke mortality that are critical to the 
2020 Strategic Impact Goals? Addressing these basic policy 
questions and the specific priority topics suggested here will 
require ongoing assessment of the AHA research enterprise. 
To the extent that these are new questions, new approaches, 
new methods, and a new cadre of cardiovascular scientists 
may be needed.
We are encouraged by this review and look forward to an 
era in which AHA exerts ever-greater influence on the under-
lying science and consequent policies for improving the CVH 
and longevity of all Americans.
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